1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

100−00−5 : 1−Chloro−4−nitrobenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

100−00−5 : 1−Chloro−4−nitrobenzene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

100−01−6 : 4−Nitroaniline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

100−01−6 : 4−Nitroaniline 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

100−02−7 : 4−Nitrophenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

100−02−7 : 4−Nitrophenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

10016−20−3 : alpha−Cyclodextrin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

10016−20−3 : alpha−Cyclodextrin 

 Agonist: 0 Antagonist: 0.00022

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

100−21−0 : Terephthalic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

100−21−0 : Terephthalic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

10025−74−8 : Dysprosium(III) chloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

10025−74−8 : Dysprosium(III) chloride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

100−37−8 : N,N−Diethylethanolamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

100−37−8 : N,N−Diethylethanolamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

10042−59−8 : 2−Propyl−1−heptanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

10042−59−8 : 2−Propyl−1−heptanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

10043−35−3 : Boric acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

10043−35−3 : Boric acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

100−51−6 : Benzyl alcohol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

100−51−6 : Benzyl alcohol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

100−54−9 : 3−Pyridinecarbonitrile 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

100−54−9 : 3−Pyridinecarbonitrile 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

100−64−1 : Cyclohexanone oxime 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

100−64−1 : Cyclohexanone oxime 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1007−28−9 : Deisopropylatrazine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1007−28−9 : Deisopropylatrazine 

 Agonist: 0.0035 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

0081−67−1 : 4−(2−Phenylpropan−2−yl)−N−[4−(2−phenylpropan−2−yl)phenyl]aniline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

10081−67−1 : 4−(2−Phenylpropan−2−yl)−N−[4−(2−phenylpropan−2−yl)phenyl]a

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1008−72−6 : Sodium 2−formylbenzenesulfonate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1008−72−6 : Sodium 2−formylbenzenesulfonate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

10094−34−5 : 1,1−Dimethyl−2−phenylethyl butanoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

10094−34−5 : 1,1−Dimethyl−2−phenylethyl butanoate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

100−97−0 : Methenamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

100−97−0 : Methenamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101−02−0 : Triphenyl phosphite 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101−02−0 : Triphenyl phosphite 

 Agonist: 0.0041 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101−05−3 : Anilazine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101−05−3 : Anilazine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101−10−0 : Cloprop 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101−10−0 : Cloprop 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101−20−2 : Triclocarban 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101−20−2 : Triclocarban 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101−21−3 : Chlorpropham 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101−21−3 : Chlorpropham 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101−37−1 : 2,4,6−Tris(allyloxy)−1,3,5−triazine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101−37−1 : 2,4,6−Tris(allyloxy)−1,3,5−triazine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101−42−8 : Fenuron 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101−42−8 : Fenuron 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101463−69−8 : Flufenoxuron 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101463−69−8 : Flufenoxuron 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101−54−2 : N−Phenyl−1,4−benzenediamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101−54−2 : N−Phenyl−1,4−benzenediamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101−55−3 : p−Bromodiphenyl ether 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101−55−3 : p−Bromodiphenyl ether 

 Agonist: 0.016 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101−61−1 : 4,4'−Methylenebis(N,N−dimethylaniline) 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101−61−1 : 4,4'−Methylenebis(N,N−dimethylaniline) 

 Agonist: 0.025 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

10161−33−8 : 17beta−Trenbolone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

10161−33−8 : 17beta−Trenbolone 

 Agonist: 0.6 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101−77−9 : 4,4'−Methylenedianiline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101−77−9 : 4,4'−Methylenedianiline 

 Agonist: 0.0081 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101−80−4 : 4,4'−Oxydianiline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101−80−4 : 4,4'−Oxydianiline 

 Agonist: 0.012 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101−81−5 : Diphenylmethane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101−81−5 : Diphenylmethane 

 Agonist: 0.025 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101−83−7 : Dicyclohexylamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101−83−7 : Dicyclohexylamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101−84−8 : Diphenyl oxide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101−84−8 : Diphenyl oxide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101−86−0 : 2−Benzylideneoctanal 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

101−86−0 : 2−Benzylideneoctanal 

 Agonist: 0.0077 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

102−06−7 : 1,3−Diphenylguanidine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

102−06−7 : 1,3−Diphenylguanidine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

10222−01−2 : 2,2−Dibromo−3−nitrilopropionamide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

10222−01−2 : 2,2−Dibromo−3−nitrilopropionamide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

102−27−2 : N−Ethyl−3−methylaniline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

102−27−2 : N−Ethyl−3−methylaniline 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1024−57−3 : Heptachlor epoxide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1024−57−3 : Heptachlor epoxide 

 Agonist: 0.014 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

102−60−3 : N,N,N',N'−Tetrakis(2−Hydroxypropyl)ethylenediamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

102−60−3 : N,N,N',N'−Tetrakis(2−Hydroxypropyl)ethylenediamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

10265−92−6 : Methamidophos 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

10265−92−6 : Methamidophos 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

102676−31−3 : Fadrozole hydrochloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

102676−31−3 : Fadrozole hydrochloride 

 Agonist: 0.075 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

102−71−6 : Triethanolamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

102−71−6 : Triethanolamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

102−76−1 : Triacetin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

102−76−1 : Triacetin 

 Agonist: 0.014 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

102−82−9 : Tributylamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

102−82−9 : Tributylamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

103055−07−8 : Lufenuron 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

103055−07−8 : Lufenuron 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

103−09−3 : 2−Ethylhexyl acetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

103−09−3 : 2−Ethylhexyl acetate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1031−07−8 : Endosulfan sulfate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1031−07−8 : Endosulfan sulfate 

 Agonist: 0 Antagonist: 0.0061

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

103−11−7 : 2−Ethylhexyl acrylate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

103−11−7 : 2−Ethylhexyl acrylate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

103−23−1 : Di(2−ethylhexyl) adipate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

103−23−1 : Di(2−ethylhexyl) adipate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

103−24−2 : Bis(2−ethylhexyl) nonanedioate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

103−24−2 : Bis(2−ethylhexyl) nonanedioate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

103−33−3 : Azobenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

103−33−3 : Azobenzene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

103−34−4 : 4,4'−Dithiodimorpholine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

103−34−4 : 4,4'−Dithiodimorpholine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

103361−09−7 : Flumioxazin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

103361−09−7 : Flumioxazin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1034−01−1 : Octyl gallate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1034−01−1 : Octyl gallate 

 Agonist: 0.044 Antagonist: 0.1

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

103−41−3 : Benzyl cinnamate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

103−41−3 : Benzyl cinnamate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

103−65−1 : Propylbenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

103−65−1 : Propylbenzene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

103−69−5 : N−Ethylaniline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

103−69−5 : N−Ethylaniline 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

103−76−4 : 1−Piperazineethanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

103−76−4 : 1−Piperazineethanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

103−90−2 : Acetaminophen 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

103−90−2 : Acetaminophen 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

104098−48−8 : Imazapic 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

104098−48−8 : Imazapic 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

104−13−2 : 4−Butylaniline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

104−13−2 : 4−Butylaniline 

 Agonist: 0.008 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

104206−82−8 : Mesotrione 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

104206−82−8 : Mesotrione 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

104−40−5 : 4−Nonylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

104−40−5 : 4−Nonylphenol 

 Agonist: 0.11 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

104−43−8 : 4−Dodecylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

104−43−8 : 4−Dodecylphenol 

 Agonist: 0.56 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

104−45−0 : 4−Propylanisole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

104−45−0 : 4−Propylanisole 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

104−51−8 : Butylbenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

104−51−8 : Butylbenzene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

10453−86−8 : Resmethrin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

10453−86−8 : Resmethrin 

 Agonist: 0.0077 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

104−54−1 : 3−Phenyl−2−propen−1−ol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

104−54−1 : 3−Phenyl−2−propen−1−ol 

 Agonist: 0.0064 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

104−61−0 : gamma−Nonanolactone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

104−61−0 : gamma−Nonanolactone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

104−66−5 : 1,2−Diphenoxyethane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

104−66−5 : 1,2−Diphenoxyethane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

104−67−6 : 5−Heptyldihydro−2(3H)−furanone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

104−67−6 : 5−Heptyldihydro−2(3H)−furanone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

104−76−7 : 2−Ethyl−1−hexanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

104−76−7 : 2−Ethyl−1−hexanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

104795−68−8 : CI−959 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

104795−68−8 : CI−959 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

105−21−5 : 1,4−Heptanolide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

105−21−5 : 1,4−Heptanolide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

105−37−3 : Ethyl propionate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

105−37−3 : Ethyl propionate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

10540−29−1 : Tamoxifen 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

10540−29−1 : Tamoxifen 

 Agonist: 0.042 Antagonist: 0.69

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

105512−06−9 : Clodinafop−propargyl mixt. 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

105512−06−9 : Clodinafop−propargyl mixt. 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

105−53−3 : Diethyl propanedioate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

105−53−3 : Diethyl propanedioate 

 Agonist: 0.0031 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

105−54−4 : Ethyl butyrate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

105−54−4 : Ethyl butyrate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

105−55−5 : N,N'−Diethylthiourea 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

105−55−5 : N,N'−Diethylthiourea 

 Agonist: 0.019 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

105−60−2 : Caprolactam 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

105−60−2 : Caprolactam 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

105624−86−0 : 5HPP−33 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

105624−86−0 : 5HPP−33 

 Agonist: 0.58 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

105−67−9 : 2,4−Dimethylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

105−67−9 : 2,4−Dimethylphenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

105−87−3 : Geranyl acetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

105−87−3 : Geranyl acetate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

105−99−7 : Dibutyl hexanedioate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

105−99−7 : Dibutyl hexanedioate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

10605−21−7 : Carbendazim 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

10605−21−7 : Carbendazim 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1061517−62−1 : PharmaGSID_47337 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1061517−62−1 : PharmaGSID_47337 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−22−9 : Citronellol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−22−9 : Citronellol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−23−0 : Citronellal 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−23−0 : Citronellal 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−24−1 : Geraniol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−24−1 : Geraniol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−25−2 : (2Z)−3,7−Dimethylocta−2,6−dien−1−ol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−25−2 : (2Z)−3,7−Dimethylocta−2,6−dien−1−ol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−27−4 : Isopentyl butyrate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−27−4 : Isopentyl butyrate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−30−9 : Ethyl heptanoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−30−9 : Ethyl heptanoate 

 Agonist: 0.015 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−43−4 : 4−Chlorotoluene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−43−4 : 4−Chlorotoluene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−44−5 : p−Cresol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−44−5 : p−Cresol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−45−6 : 4−Thiocresol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−45−6 : 4−Thiocresol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−46−7 : 1,4−Dichlorobenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−46−7 : 1,4−Dichlorobenzene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−47−8 : 4−Chloroaniline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−47−8 : 4−Chloroaniline 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−48−9 : 4−Chlorophenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−48−9 : 4−Chlorophenol 

 Agonist: 0.05 Antagonist: 0.019

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−49−0 : 4−Methylaniline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−49−0 : 4−Methylaniline 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−50−3 : 1,4−Benzenediamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−50−3 : 1,4−Benzenediamine 

 Agonist: 0.02 Antagonist: 0.025

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−65−0 : Dimethyl succinate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−65−0 : Dimethyl succinate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−68−3 : 3−Octanone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−68−3 : 3−Octanone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1067−25−0 : Trimethoxypropylsilane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1067−25−0 : Trimethoxypropylsilane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1067−53−4 : Tris(2−methoxyethoxy)vinylsilane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1067−53−4 : Tris(2−methoxyethoxy)vinylsilane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−87−6 : 4−Vinyl−1−cyclohexene dioxide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−87−6 : 4−Vinyl−1−cyclohexene dioxide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1068967−96−3 : SAR102608 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1068967−96−3 : SAR102608 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−93−4 : 1,2−Dibromoethane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

106−93−4 : 1,2−Dibromoethane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

107−07−3 : 2−Chloroethanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

107−07−3 : 2−Chloroethanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

107−13−1 : Acrylonitrile 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

107−13−1 : Acrylonitrile 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

107−18−6 : Allyl alcohol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

107−18−6 : Allyl alcohol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

107−20−0 : Chloroacetaldehyde 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

107−20−0 : Chloroacetaldehyde 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

107−21−1 : Ethylene glycol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

107−21−1 : Ethylene glycol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1072−15−7 : Sulfuric acid, monononyl ester, sodium salt 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1072−15−7 : Sulfuric acid, monononyl ester, sodium salt 

 Agonist: 0.091 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

107−30−2 : Chloromethyl methyl ether 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

107−30−2 : Chloromethyl methyl ether 

 Agonist: 0.02 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

107−41−5 : 2−Methyl−2,4−pentanediol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

107−41−5 : 2−Methyl−2,4−pentanediol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

107−46−0 : Hexamethyldisiloxane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

107−46−0 : Hexamethyldisiloxane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

107−51−7 : Octamethyltrisiloxane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

107−51−7 : Octamethyltrisiloxane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

107534−96−3 : Tebuconazole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

107534−96−3 : Tebuconazole 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

107−54−0 : 3,5−Dimethyl−1−hexyn−3−ol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

107−54−0 : 3,5−Dimethyl−1−hexyn−3−ol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1076−97−7 : 1,4−Cyclohexanedicarboxylic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1076−97−7 : 1,4−Cyclohexanedicarboxylic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

107−75−5 : 7−Hydroxy−3,7−dimethyloctanal 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

107−75−5 : 7−Hydroxy−3,7−dimethyloctanal 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

107−87−9 : 2−Pentanone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

107−87−9 : 2−Pentanone 

 Agonist: 0.0029 Antagonist: 0.0076

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

107−88−0 : 1,3−Butanediol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

107−88−0 : 1,3−Butanediol 

 Agonist: 0.00018 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

107−92−6 : Butanoic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

107−92−6 : Butanoic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

107−98−2 : 1−Methoxy−2−propanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

107−98−2 : 1−Methoxy−2−propanol 

 Agonist: 0.015 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−01−0 : Dimethylaminoethanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−01−0 : Dimethylaminoethanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−11−2 : 4−Methyl−2−pentanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−11−2 : 4−Methyl−2−pentanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−21−4 : Isopropyl acetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−21−4 : Isopropyl acetate 

 Agonist: 0.024 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−32−7 : Propylene carbonate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−32−7 : Propylene carbonate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−38−3 : 1,3−Dimethylbenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−38−3 : 1,3−Dimethylbenzene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−39−4 : m−Cresol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−39−4 : m−Cresol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108419−33−6 : Acetic acid, C8−10−branched alkyl esters, C9−rich 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108419−33−6 : Acetic acid, C8−10−branched alkyl esters, C9−rich 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−44−1 : 3−Methylaniline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−44−1 : 3−Methylaniline 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−45−2 : 1,3−Benzenediamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−45−2 : 1,3−Benzenediamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−46−3 : Resorcinol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−46−3 : Resorcinol 

 Agonist: 0.0057 Antagonist: 0.014

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1085−12−7 : Heptylparaben 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1085−12−7 : Heptylparaben 

 Agonist: 0.38 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−59−8 : Dimethyl malonate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−59−8 : Dimethyl malonate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−67−8 : 1,3,5−Trimethylbenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−67−8 : 1,3,5−Trimethylbenzene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−68−9 : 3,5−Dimethylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−68−9 : 3,5−Dimethylphenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−77−0 : 2,4,6−Trichloro−s−triazine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−77−0 : 2,4,6−Trichloro−s−triazine 

 Agonist: 0.0051 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−80−5 : Cyanuric acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−80−5 : Cyanuric acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−83−8 : Diisobutyl ketone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−83−8 : Diisobutyl ketone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−91−8 : Cyclohexylamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−91−8 : Cyclohexylamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−93−0 : Cyclohexanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−93−0 : Cyclohexanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−94−1 : Cyclohexanone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−94−1 : Cyclohexanone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−95−2 : Phenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−95−2 : Phenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−98−5 : Benzenethiol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

108−98−5 : Benzenethiol 

 Agonist: 0.008 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

109−02−4 : 4−Methylmorpholine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

109−02−4 : 4−Methylmorpholine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

109−43−3 : Dibutyl decanedioate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

109−43−3 : Dibutyl decanedioate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

109−46−6 : N,N'−Dibutylthiourea 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

109−46−6 : N,N'−Dibutylthiourea 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

109−52−4 : Pentanoic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

109−52−4 : Pentanoic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

109−55−7 : 3−(Dimethylamino)propylamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

109−55−7 : 3−(Dimethylamino)propylamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1095−90−5 : Methadone hydrochloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1095−90−5 : Methadone hydrochloride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

109−77−3 : Propanedinitrile 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

109−77−3 : Propanedinitrile 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

109−86−4 : 2−Methoxyethanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

109−86−4 : 2−Methoxyethanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−05−4 : Di−tert−butyl peroxide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−05−4 : Di−tert−butyl peroxide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−12−3 : 5−Methyl−2−hexanone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−12−3 : 5−Methyl−2−hexanone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−15−6 : Butanedioic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−15−6 : Butanedioic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−16−7 : Maleic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−16−7 : Maleic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−17−8 : Fumaric acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−17−8 : Fumaric acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110235−47−7 : Mepanipyrim 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110235−47−7 : Mepanipyrim 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−25−8 : Oleyl sarcosine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−25−8 : Oleyl sarcosine 

 Agonist: 0 Antagonist: 0.017

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−26−9 : N,N'−Methylenebisacrylamide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−26−9 : N,N'−Methylenebisacrylamide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−27−0 : Isopropyl tetradecanoic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−27−0 : Isopropyl tetradecanoic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−33−8 : Dihexyl hexanedioate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−33−8 : Dihexyl hexanedioate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−42−9 : Methyl decanoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−42−9 : Methyl decanoate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−43−0 : 2−Heptanone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−43−0 : 2−Heptanone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−44−1 : Sorbic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−44−1 : Sorbic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110488−70−5 : Dimethomorph 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110488−70−5 : Dimethomorph 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−62−3 : Pentanal 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−62−3 : Pentanal 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−63−4 : 1,4−Butanediol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−63−4 : 1,4−Butanediol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−65−6 : 2−Butyne−1,4−diol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−65−6 : 2−Butyne−1,4−diol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−69−0 : Butanal oxime 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−69−0 : Butanal oxime 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−73−6 : 2−(Ethylamino)ethanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−73−6 : 2−(Ethylamino)ethanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−80−5 : 2−Ethoxyethanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−80−5 : 2−Ethoxyethanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−85−0 : Piperazine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−85−0 : Piperazine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−87−2 : 3,4−Dihydro−2H−pyran 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−87−2 : 3,4−Dihydro−2H−pyran 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−91−8 : Morpholine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−91−8 : Morpholine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−97−4 : Diisopropanolamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

110−97−4 : Diisopropanolamine 

 Agonist: 0.088 Antagonist: 0.0027

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

11099−07−3 : Glyceryl stearates 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

11099−07−3 : Glyceryl stearates 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−11−5 : Methyl octanoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−11−5 : Methyl octanoate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−14−8 : Heptanoic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−14−8 : Heptanoic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−15−9 : 2−Ethoxyethyl acetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−15−9 : 2−Ethoxyethyl acetate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1111−78−0 : Ammonium carbamate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1111−78−0 : Ammonium carbamate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−20−6 : Decanedioic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−20−6 : Decanedioic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−21−7 : Triethylene glycol diacetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−21−7 : Triethylene glycol diacetate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1112−39−6 : Dimethoxydimethylsilane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1112−39−6 : Dimethoxydimethylsilane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−27−3 : 1−Hexanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−27−3 : 1−Hexanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−30−8 : Glutaraldehyde 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−30−8 : Glutaraldehyde 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−40−0 : Diethylenetriamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−40−0 : Diethylenetriamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−42−2 : Diethanolamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−42−2 : Diethanolamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−44−4 : Bis(2−chloroethyl) ether 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−44−4 : Bis(2−chloroethyl) ether 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−46−6 : Diethylene glycol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−46−6 : Diethylene glycol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1114−71−2 : Pebulate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1114−71−2 : Pebulate 

 Agonist: 0.0041 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−49−9 : Hexamethyleneimine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−49−9 : Hexamethyleneimine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−55−7 : 1,2−Ethanediol diacetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−55−7 : 1,2−Ethanediol diacetate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−62−6 : Ethyl oleate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−62−6 : Ethyl oleate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−69−3 : Hexanedinitrile 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−69−3 : Hexanedinitrile 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−70−6 : 1−Heptanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−70−6 : 1−Heptanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−71−7 : Heptanal 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−71−7 : Heptanal 

 Agonist: 0.03 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−76−2 : 2−Butoxyethanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−76−2 : 2−Butoxyethanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−77−3 : Diethylene glycol monomethyl ether 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−77−3 : Diethylene glycol monomethyl ether 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111812−58−9 : Fenpyroximate (Z,E) 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111812−58−9 : Fenpyroximate (Z,E) 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−82−0 : Methyl dodecanoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−82−0 : Methyl dodecanoate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−84−2 : Nonane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−84−2 : Nonane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1118−46−3 : Butyltin trichloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1118−46−3 : Butyltin trichloride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−87−5 : 1−Octanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−87−5 : 1−Octanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1118−92−9 : N,N−Dimethyloctanamide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1118−92−9 : N,N−Dimethyloctanamide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−90−0 : 2−(2−Ethoxyethoxy)ethanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−90−0 : 2−(2−Ethoxyethoxy)ethanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1119−40−0 : Dimethyl glutarate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1119−40−0 : Dimethyl glutarate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−96−6 : Bis(2−methoxyethyl) ether 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111−96−6 : Bis(2−methoxyethyl) ether 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111988−49−9 : Thiacloprid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111988−49−9 : Thiacloprid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111991−09−4 : Nicosulfuron 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

111991−09−4 : Nicosulfuron 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1120−01−0 : Sodium hexyldecyl sulfate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1120−01−0 : Sodium hexyldecyl sulfate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1120−04−3 : Octadecyl sulfate sodium salt 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1120−04−3 : Octadecyl sulfate sodium salt 

 Agonist: 0.0045 Antagonist: 0.018

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−00−5 : Dodecyltrimethylammonium chloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−00−5 : Dodecyltrimethylammonium chloride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1120−21−4 : Undecane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1120−21−4 : Undecane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−05−0 : Nonanoic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−05−0 : Nonanoic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1120−71−4 : 1,3−Propane sultone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1120−71−4 : 1,3−Propane sultone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−07−2 : 2−Butoxyethyl acetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−07−2 : 2−Butoxyethyl acetate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−12−9 : 2−Undecanone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−12−9 : 2−Undecanone 

 Agonist: 0.0019 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−14−1 : Octyl acetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−14−1 : Octyl acetate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−18−5 : N,N−Dimethyldodecan−1−amine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−18−5 : N,N−Dimethyldodecan−1−amine 

 Agonist: 0 Antagonist: 2.2e−20

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112226−61−6 : Halofenozide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112226−61−6 : Halofenozide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−25−4 : 2−(Hexyloxy)ethanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−25−4 : 2−(Hexyloxy)ethanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−27−6 : Triethylene glycol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−27−6 : Triethylene glycol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112281−77−3 : Tetraconazole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112281−77−3 : Tetraconazole 

 Agonist: 0 Antagonist: 0.012

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−30−1 : 1−Decanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−30−1 : 1−Decanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−31−2 : Decanal 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−31−2 : Decanal 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−34−5 : 2−(2−Butoxyethoxy)ethanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−34−5 : 2−(2−Butoxyethoxy)ethanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−35−6 : 2−[2−(2−Methoxyethoxy)ethoxy]ethanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−35−6 : 2−[2−(2−Methoxyethoxy)ethoxy]ethanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−38−9 : 10−Undecenoic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−38−9 : 10−Undecenoic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112410−23−8 : Tebufenozide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112410−23−8 : Tebufenozide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−42−5 : 1−Undecanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−42−5 : 1−Undecanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−49−2 : Triethylene glycol dimethyl ether 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−49−2 : Triethylene glycol dimethyl ether 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−50−5 : 2−[2−(2−Ethoxyethoxy)ethoxy]ethanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−50−5 : 2−[2−(2−Ethoxyethoxy)ethoxy]ethanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112529−15−4 : Pioglitazone hydrochloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112529−15−4 : Pioglitazone hydrochloride 

 Agonist: 0.0058 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−53−8 : 1−Dodecanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−53−8 : 1−Dodecanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−55−0 : 1−Dodecanethiol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−55−0 : 1−Dodecanethiol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−60−7 : Tetraethylene glycol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−60−7 : Tetraethylene glycol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−63−0 : Methyl linoleate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−63−0 : Methyl linoleate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−70−9 : 1−Tridecanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−70−9 : 1−Tridecanol 

 Agonist: 0.004 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−72−1 : 1−Tetradecanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−72−1 : 1−Tetradecanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112733−06−9 : Zenarestat 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112733−06−9 : Zenarestat 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−80−1 : Oleic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112−80−1 : Oleic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112809−51−5 : Letrozole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

112809−51−5 : Letrozole 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

113136−77−9 : Cyclanilide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

113136−77−9 : Cyclanilide 

 Agonist: 0 Antagonist: 8.6e−05

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1134−23−2 : Cycloate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1134−23−2 : Cycloate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

113−48−4 : MGK−264 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

113−48−4 : MGK−264 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

113734−18−2 : CP−114271 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

113734−18−2 : CP−114271 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

114−07−8 : Erythromycin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

114−07−8 : Erythromycin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

114−26−1 : Propoxur 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

114−26−1 : Propoxur 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

114311−32−9 : Imazamox 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

114311−32−9 : Imazamox 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1143−38−0 : Anthralin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1143−38−0 : Anthralin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

114369−43−6 : Fenbuconazole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

114369−43−6 : Fenbuconazole 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

115−28−6 : Chlorendic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

115−28−6 : Chlorendic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

115−29−7 : Endosulfan 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

115−29−7 : Endosulfan 

 Agonist: 0.034 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

115−32−2 : Dicofol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

115−32−2 : Dicofol 

 Agonist: 0 Antagonist: 0.039

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

115−39−9 : Bromophenol blue 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

115−39−9 : Bromophenol blue 

 Agonist: 0 Antagonist: 0.028

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1156−19−0 : Tolazamide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1156−19−0 : Tolazamide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

115−77−5 : Pentaerythritol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

115−77−5 : Pentaerythritol 

 Agonist: 0 Antagonist: 4e−05

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

115−86−6 : Triphenyl phosphate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

115−86−6 : Triphenyl phosphate 

 Agonist: 0.099 Antagonist: 0.061

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

115−95−7 : Linalyl acetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

115−95−7 : Linalyl acetate 

 Agonist: 0 Antagonist: 8.8e−05

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

115−96−8 : Tris(2−chloroethyl) phosphate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

115−96−8 : Tris(2−chloroethyl) phosphate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

116−02−9 : 3,3,5−Trimethylcyclohexanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

116−02−9 : 3,3,5−Trimethylcyclohexanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

116−06−3 : Aldicarb 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

116−06−3 : Aldicarb 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

116255−48−2 : Bromuconazole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

116255−48−2 : Bromuconazole 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

116−25−6 : 1−(Hydroxymethyl)−5,5−dimethylhydantoin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

116−25−6 : 1−(Hydroxymethyl)−5,5−dimethylhydantoin 

 Agonist: 0.016 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1166−52−5 : Dodecyl gallate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1166−52−5 : Dodecyl gallate 

 Agonist: 0.004 Antagonist: 0.086

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

116714−46−6 : Novaluron 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

116714−46−6 : Novaluron 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

117−08−8 : Tetrachlorophthalic anhydride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

117−08−8 : Tetrachlorophthalic anhydride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

117337−19−6 : Fluthiacet−methyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

117337−19−6 : Fluthiacet−methyl 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

117−39−5 : Quercetin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

117−39−5 : Quercetin 

 Agonist: 0.12 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

117428−22−5 : Picoxystrobin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

117428−22−5 : Picoxystrobin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

117718−60−2 : Thiazopyr 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

117718−60−2 : Thiazopyr 

 Agonist: 0.023 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

117−79−3 : 2−Aminoanthraquinone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

117−79−3 : 2−Aminoanthraquinone 

 Agonist: 0.036 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

117−80−6 : Dichlone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

117−80−6 : Dichlone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

117−81−7 : Di(2−ethylhexyl) phthalate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

117−81−7 : Di(2−ethylhexyl) phthalate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

117−84−0 : Dioctyl phthalate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

117−84−0 : Dioctyl phthalate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

117−99−7 : 2−Hydroxybenzophenone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

117−99−7 : 2−Hydroxybenzophenone 

 Agonist: 0.029 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

118134−30−8 : Spiroxamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

118134−30−8 : Spiroxamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

18−47−8 : 1H−Pyrazole−3−carboxylic acid, 4,5−dihydro−5−oxo−1−(4−sulfophenyl)− 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

118−47−8 : 1H−Pyrazole−3−carboxylic acid, 4,5−dihydro−5−oxo−1−(4−sulfoph

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

118−52−5 : 1,3−Dichloro−5,5−dimethylhydantoin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

118−52−5 : 1,3−Dichloro−5,5−dimethylhydantoin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

118−55−8 : Phenyl salicylate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

118−55−8 : Phenyl salicylate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

118−56−9 : 3,3,5−Trimethylcyclohexyl salicylate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

118−56−9 : 3,3,5−Trimethylcyclohexyl salicylate 

 Agonist: 0.041 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

118−58−1 : Benzyl salicylate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

118−58−1 : Benzyl salicylate 

 Agonist: 0.019 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

118−71−8 : Maltol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

118−71−8 : Maltol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

118−79−6 : 2,4,6−Tribromophenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

118−79−6 : 2,4,6−Tribromophenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

118−82−1 : 4,4'−Methylenebis(2,6−di−t−butylphenol) 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

118−82−1 : 4,4'−Methylenebis(2,6−di−t−butylphenol) 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1189−08−8 : 1,3−Butyleneglycol dimethacrylate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1189−08−8 : 1,3−Butyleneglycol dimethacrylate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

118−93−4 : 2−Hydroxyacetophenone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

118−93−4 : 2−Hydroxyacetophenone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

119−07−3 : Octyl decyl phthalate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

119−07−3 : Octyl decyl phthalate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1191−50−0 : Sodium myristyl sulfate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1191−50−0 : Sodium myristyl sulfate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

119168−77−3 : Tebufenpyrad 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

119168−77−3 : Tebufenpyrad 

 Agonist: 0 Antagonist: 0.00015

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1192−52−5 : 4,5−Dichloro−3H−1,2−dithiol−3−one 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1192−52−5 : 4,5−Dichloro−3H−1,2−dithiol−3−one 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

119−36−8 : Methyl salicylate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

119−36−8 : Methyl salicylate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

119446−68−3 : Difenoconazole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

119446−68−3 : Difenoconazole 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1194−65−6 : Dichlobenil 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1194−65−6 : Dichlobenil 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

119−47−1 : 2,2'−Methylenebis(4−methyl−6−tert−butylphenol) 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

119−47−1 : 2,2'−Methylenebis(4−methyl−6−tert−butylphenol) 

 Agonist: 0.001 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

119515−38−7 : Icaridin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

119515−38−7 : Icaridin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

119−53−9 : Benzoin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

119−53−9 : Benzoin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

119−61−9 : Benzophenone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

119−61−9 : Benzophenone 

 Agonist: 0.059 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

119−64−2 : Tetralin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

119−64−2 : Tetralin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

119−90−4 : 3,3'−Dimethoxybenzidine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

119−90−4 : 3,3'−Dimethoxybenzidine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

119−93−7 : 3,3'−Dimethylbenzidine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

119−93−7 : 3,3'−Dimethylbenzidine 

 Agonist: 0.1 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120068−37−3 : Fipronil 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120068−37−3 : Fipronil 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120116−88−3 : Cyazofamid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120116−88−3 : Cyazofamid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−12−7 : Anthracene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−12−7 : Anthracene 

 Agonist: 0.008 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−14−9 : Veratraldehyde 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−14−9 : Veratraldehyde 

 Agonist: 0.035 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−18−3 : Naphthalene−2−sulfonic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−18−3 : Naphthalene−2−sulfonic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−32−1 : Clorophene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−32−1 : Clorophene 

 Agonist: 0.096 Antagonist: 0.043

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−36−5 : Dichlorprop 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−36−5 : Dichlorprop 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−46−7 : 1,3−Diphenyl−1,3−propanedione 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−46−7 : 1,3−Diphenyl−1,3−propanedione 

 Agonist: 0.049 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−47−8 : Ethylparaben 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−47−8 : Ethylparaben 

 Agonist: 0.12 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120511−73−1 : Anastrozole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120511−73−1 : Anastrozole 

 Agonist: 0.018 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−51−4 : Benzyl benzoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−51−4 : Benzyl benzoate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−55−8 : Diethylene glycol dibenzoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−55−8 : Diethylene glycol dibenzoate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−56−9 : Triethylene glycol dibenzoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−56−9 : Triethylene glycol dibenzoate 

 Agonist: 0.03 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−61−6 : Dimethyl terephthalate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−61−6 : Dimethyl terephthalate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−65−0 : 2−((Dimethylamino)methyl)phenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−65−0 : 2−((Dimethylamino)methyl)phenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−71−8 : 2−Methoxy−5−methylaniline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−71−8 : 2−Methoxy−5−methylaniline 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−72−9 : Indole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−72−9 : Indole 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−80−9 : Catechol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−80−9 : Catechol 

 Agonist: 0.014 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−82−1 : 1,2,4−Trichlorobenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−82−1 : 1,2,4−Trichlorobenzene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−83−2 : 2,4−Dichlorophenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−83−2 : 2,4−Dichlorophenol 

 Agonist: 0.011 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−92−3 : Cyclopentanone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−92−3 : Cyclopentanone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−95−6 : 2,4−Bis(2−methylbutan−2−yl)phenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−95−6 : 2,4−Bis(2−methylbutan−2−yl)phenol 

 Agonist: 0.0086 Antagonist: 0.005

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

121−00−6 : 2−tert−Butyl−4−methoxyphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

121−00−6 : 2−tert−Butyl−4−methoxyphenol 

 Agonist: 0.02 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

8−13−3 : Manganese, tricarbonyl[(1,2,3,4,5−.eta.)−1−methyl−2,4−cyclopentadien−1−yl]− 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

12108−13−3 : Manganese, tricarbonyl[(1,2,3,4,5−.eta.)−1−methyl−2,4−cyclopentad

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

121−14−2 : 2,4−Dinitrotoluene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

121−14−2 : 2,4−Dinitrotoluene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

121−32−4 : 3−Ethoxy−4−hydroxybenzaldehyde 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

121−32−4 : 3−Ethoxy−4−hydroxybenzaldehyde 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

121−33−5 : 4−Hydroxy−3−methoxybenzaldehyde 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

121−33−5 : 4−Hydroxy−3−methoxybenzaldehyde 

 Agonist: 1.8e−05 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

121−39−1 : Ethyl 3−phenylglycidate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

121−39−1 : Ethyl 3−phenylglycidate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1214−39−7 : N−Benzyladenine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1214−39−7 : N−Benzyladenine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

121552−61−2 : Cyprodinil 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

121552−61−2 : Cyprodinil 

 Agonist: 0.032 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

121−69−7 : N,N−Dimethylaniline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

121−69−7 : N,N−Dimethylaniline 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

121−75−5 : Malathion 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

121−75−5 : Malathion 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

121−79−9 : Propyl gallate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

121−79−9 : Propyl gallate 

 Agonist: 0.097 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

121−91−5 : 1,3−Benzenedicarboxylic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

121−91−5 : 1,3−Benzenedicarboxylic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1219−38−1 : Octylparaben 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1219−38−1 : Octylparaben 

 Agonist: 0.38 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

122008−85−9 : Cyhalofop−butyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

122008−85−9 : Cyhalofop−butyl 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

122−14−5 : Fenitrothion 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

122−14−5 : Fenitrothion 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

122−20−3 : Triisopropanolamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

122−20−3 : Triisopropanolamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

122−34−9 : Simazine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

122−34−9 : Simazine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

122−39−4 : Diphenylamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

122−39−4 : Diphenylamine 

 Agonist: 0.02 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

122−40−7 : Pentylcinnamaldehyde 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

122−40−7 : Pentylcinnamaldehyde 

 Agonist: 0.0064 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

122−42−9 : Propham 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

122−42−9 : Propham 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

122453−73−0 : Chlorfenapyr 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

122453−73−0 : Chlorfenapyr 

 Agonist: 0 Antagonist: 0.062

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

122−51−0 : Ethyl orthoformate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

122−51−0 : Ethyl orthoformate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

122−57−6 : Methyl styryl ketone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

122−57−6 : Methyl styryl ketone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

122−66−7 : 1,2−Diphenylhydrazine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

122−66−7 : 1,2−Diphenylhydrazine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

122−78−1 : Phenylacetaldehyde 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

122−78−1 : Phenylacetaldehyde 

 Agonist: 0.0029 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

122836−35−5 : Sulfentrazone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

122836−35−5 : Sulfentrazone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

122−88−3 : 4−Chlorophenoxyacetic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

122−88−3 : 4−Chlorophenoxyacetic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

122−99−6 : 2−Phenoxyethanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

122−99−6 : 2−Phenoxyethanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123−00−2 : 4−Morpholinepropanamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123−00−2 : 4−Morpholinepropanamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123−05−7 : 2−Ethylhexanal 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123−05−7 : 2−Ethylhexanal 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123−07−9 : 4−Ethylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123−07−9 : 4−Ethylphenol 

 Agonist: 0.0069 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123−11−5 : 4−Methoxybenzaldehyde 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123−11−5 : 4−Methoxybenzaldehyde 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123122−55−4 : Candoxatril 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123122−55−4 : Candoxatril 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123−17−1 : 2,6,8−Trimethyl−4−nonanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123−17−1 : 2,6,8−Trimethyl−4−nonanol 

 Agonist: 0.0026 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123−25−1 : Diethyl butanedioate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123−25−1 : Diethyl butanedioate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123312−89−0 : Pymetrozine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123312−89−0 : Pymetrozine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123−31−9 : Hydroquinone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123−31−9 : Hydroquinone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123−33−1 : Maleic hydrazide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123−33−1 : Maleic hydrazide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123343−16−8 : Pyrithiobac−sodium 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123343−16−8 : Pyrithiobac−sodium 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123−35−3 : Myrcene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123−35−3 : Myrcene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123−42−2 : Diacetone alcohol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123−42−2 : Diacetone alcohol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123−66−0 : Ethyl hexanoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123−66−0 : Ethyl hexanoate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123−77−3 : Azodicarbonamide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123−77−3 : Azodicarbonamide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123−92−2 : 3−Methylbutyl acetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123−92−2 : 3−Methylbutyl acetate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123−96−6 : 2−Octanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123−96−6 : 2−Octanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123−99−9 : Nonanedioic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

123−99−9 : Nonanedioic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

124−04−9 : Hexanedioic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

124−04−9 : Hexanedioic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

124−07−2 : Octanoic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

124−07−2 : Octanoic acid 

 Agonist: 0.0059 Antagonist: 0.015

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

124−09−4 : 1,6−Hexanediamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

124−09−4 : 1,6−Hexanediamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

124−13−0 : Octanal 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

124−13−0 : Octanal 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

124−18−5 : Decane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

124−18−5 : Decane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1241−94−7 : 2−Ethylhexyl diphenyl phosphate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1241−94−7 : 2−Ethylhexyl diphenyl phosphate 

 Agonist: 0.022 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

124−19−6 : Nonanal 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

124−19−6 : Nonanal 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

124−22−1 : 1−Dodecanamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

124−22−1 : 1−Dodecanamine 

 Agonist: 0.18 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

12427−38−2 : Maneb 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

12427−38−2 : Maneb 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

124378−77−4 : Enadoline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

124378−77−4 : Enadoline 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

124−40−3 : Dimethylamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

124−40−3 : Dimethylamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

124495−18−7 : Quinoxyfen 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

124495−18−7 : Quinoxyfen 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

124−68−5 : 2−Amino−2−methylpropan−1−ol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

124−68−5 : 2−Amino−2−methylpropan−1−ol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

124−76−5 : Isoborneol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

124−76−5 : Isoborneol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

124−94−7 : Triamcinolone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

124−94−7 : Triamcinolone 

 Agonist: 0.057 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

125116−23−6 : Metconazole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

125116−23−6 : Metconazole 

 Agonist: 0.0076 Antagonist: 0.033

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

125−12−2 : Isobornyl acetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

125−12−2 : Isobornyl acetate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

125225−28−7 : Ipconazole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

125225−28−7 : Ipconazole 

 Agonist: 0 Antagonist: 0.014

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

125401−92−5 : Bispyribac−sodium 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

125401−92−5 : Bispyribac−sodium 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

125−84−8 : Aminoglutethimide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

125−84−8 : Aminoglutethimide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

126−00−1 : Diphenolic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

126−00−1 : Diphenolic acid 

 Agonist: 0.2 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1260−17−9 : Carminic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1260−17−9 : Carminic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

126−06−7 : 3−Bromo−1−chloro−5,5−dimethylhydantoin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

126−06−7 : 3−Bromo−1−chloro−5,5−dimethylhydantoin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

126−11−4 : 2−(Hydroxymethyl)−2−nitro−1,3−propanediol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

126−11−4 : 2−(Hydroxymethyl)−2−nitro−1,3−propanediol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

126−14−7 : Sucrose octaacetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

126−14−7 : Sucrose octaacetate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

126−30−7 : 2,2−Dimethylpropane−1,3−diol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

126−30−7 : 2,2−Dimethylpropane−1,3−diol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

126−72−7 : Tris(2,3−dibromopropyl) phosphate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

126−72−7 : Tris(2,3−dibromopropyl) phosphate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

126−73−8 : Tributyl phosphate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

126−73−8 : Tributyl phosphate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

126833−17−8 : Fenhexamid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

126833−17−8 : Fenhexamid 

 Agonist: 0.21 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

126−86−3 : 2,4,7,9−Tetramethyl−5−decyne−4,7−diol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

126−86−3 : 2,4,7,9−Tetramethyl−5−decyne−4,7−diol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

126−92−1 : Sodium ethasulfate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

126−92−1 : Sodium ethasulfate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

126−98−7 : Methacrylonitrile 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

126−98−7 : Methacrylonitrile 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

127−07−1 : Hydroxyurea 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

127−07−1 : Hydroxyurea 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

127−19−5 : N,N−Dimethylacetamide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

127−19−5 : N,N−Dimethylacetamide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

127−25−3 : Methyl abietate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

127−25−3 : Methyl abietate 

 Agonist: 0.0093 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

127308−82−1 : Zamifenacin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

127308−82−1 : Zamifenacin 

 Agonist: 0.049 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

127−39−9 : Sodium 1,4−diisobutyl sulfosuccinate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

127−39−9 : Sodium 1,4−diisobutyl sulfosuccinate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

127−41−3 : alpha−Ionone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

127−41−3 : alpha−Ionone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

127−47−9 : Retinol acetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

127−47−9 : Retinol acetate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

127−51−5 : alpha−Isomethylionone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

127−51−5 : alpha−Isomethylionone 

 Agonist: 0.016 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

128−04−1 : Sodium dimethyldithiocarbamate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

128−04−1 : Sodium dimethyldithiocarbamate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

128−37−0 : Butylated hydroxytoluene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

128−37−0 : Butylated hydroxytoluene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

128−39−2 : 2,6−Di−tert−butylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

128−39−2 : 2,6−Di−tert−butylphenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

128639−02−1 : Carfentrazone−ethyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

128639−02−1 : Carfentrazone−ethyl 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

128−95−0 : 1,4−Diaminoanthraquinone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

128−95−0 : 1,4−Diaminoanthraquinone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

129−00−0 : Pyrene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

129−00−0 : Pyrene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

129−06−6 : Sodium warfarin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

129−06−6 : Sodium warfarin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

129−17−9 : Sulfan blue 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

129−17−9 : Sulfan blue 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

129453−61−8 : Fulvestrant 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

129453−61−8 : Fulvestrant 

 Agonist: 0 Antagonist: 0.91

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

129630−19−9 : Pyraflufen−ethyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

129630−19−9 : Pyraflufen−ethyl 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1300−72−7 : Sodium xylenesulfonate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1300−72−7 : Sodium xylenesulfonate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1300−73−8 : Dimethylaniline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1300−73−8 : Dimethylaniline 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

130−14−3 : Sodium 1−naphthalenesulfonate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

130−14−3 : Sodium 1−naphthalenesulfonate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1303−11−3 : Indium arsenide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1303−11−3 : Indium arsenide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13071−79−9 : Terbufos 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13071−79−9 : Terbufos 

 Agonist: 0.063 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

131−11−3 : Dimethyl phthalate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

131−11−3 : Dimethyl phthalate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

131−17−9 : Diallyl phthalate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

131−17−9 : Diallyl phthalate 

 Agonist: 0.021 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

131−18−0 : Dipentyl phthalate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

131−18−0 : Dipentyl phthalate 

 Agonist: 0.024 Antagonist: 0.06

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

131341−86−1 : Fludioxonil 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

131341−86−1 : Fludioxonil 

 Agonist: 0.056 Antagonist: 0.0066

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

131−55−5 : 2,2',4,4'−Tetrahydroxybenzophenone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

131−55−5 : 2,2',4,4'−Tetrahydroxybenzophenone 

 Agonist: 0.56 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

131−56−6 : 2,4−Dihydroxybenzophenone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

131−56−6 : 2,4−Dihydroxybenzophenone 

 Agonist: 0.4 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

131−57−7 : 2−Hydroxy−4−methoxybenzophenone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

131−57−7 : 2−Hydroxy−4−methoxybenzophenone 

 Agonist: 0.092 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

131−70−4 : Monobutyl phthalate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

131−70−4 : Monobutyl phthalate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13171−00−1 : 1−(6−tert−Butyl−1,1−dimethyl−2,3−dihydro−1H−inden−4−yl)ethanone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13171−00−1 : 1−(6−tert−Butyl−1,1−dimethyl−2,3−dihydro−1H−inden−4−yl)etha

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

131807−57−3 : Famoxadone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

131807−57−3 : Famoxadone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

131860−33−8 : Azoxystrobin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

131860−33−8 : Azoxystrobin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13194−48−4 : Ethoprop 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13194−48−4 : Ethoprop 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

131983−72−7 : Triticonazole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

131983−72−7 : Triticonazole 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1320−07−6 : C.I. Acid Orange 24, monosodium salt 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1320−07−6 : C.I. Acid Orange 24, monosodium salt 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1321−74−0 : Divinylbenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1321−74−0 : Divinylbenzene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1323−19−9 : Sodium 2,4,7−tri(propan−2−yl)naphthalene−1−sulfonate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1323−19−9 : Sodium 2,4,7−tri(propan−2−yl)naphthalene−1−sulfonate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1323−38−2 : Glyceryl monoricinoleate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1323−38−2 : Glyceryl monoricinoleate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13254−34−7 : 2,6−Dimethyl−2−heptanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13254−34−7 : 2,6−Dimethyl−2−heptanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

132−64−9 : Dibenzofuran 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

132−64−9 : Dibenzofuran 

 Agonist: 0.0044 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

132−65−0 : Dibenzothiophene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

132−65−0 : Dibenzothiophene 

 Agonist: 0.0063 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13292−46−1 : Rifampicin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13292−46−1 : Rifampicin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13301−61−6 : C.I. Disperse Orange 37 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13301−61−6 : C.I. Disperse Orange 37 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

133−06−2 : Captan 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

133−06−2 : Captan 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

133−07−3 : Folpet 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

133−07−3 : Folpet 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1330−78−5 : Tricresyl phosphate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1330−78−5 : Tricresyl phosphate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1330−86−5 : Diisooctyl adipate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1330−86−5 : Diisooctyl adipate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13311−84−7 : Flutamide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13311−84−7 : Flutamide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1333−39−7 : Phenolsulfonic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1333−39−7 : Phenolsulfonic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1335−46−2 : Ionone, methyl− 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1335−46−2 : Ionone, methyl− 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1338−43−8 : Sorbitan, mono−(9Z)−9−octadecenoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1338−43−8 : Sorbitan, mono−(9Z)−9−octadecenoate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

133855−98−8 : Epoxiconazole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

133855−98−8 : Epoxiconazole 

 Agonist: 0 Antagonist: 0.04

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

133−90−4 : Chloramben 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

133−90−4 : Chloramben 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

134002−60−1 : CP−085958 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

134002−60−1 : CP−085958 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

134−03−2 : Sodium L−ascorbate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

134−03−2 : Sodium L−ascorbate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

134−20−3 : Methyl 2−aminobenzoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

134−20−3 : Methyl 2−aminobenzoate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

134−31−6 : 8−Hydroxyquinoline sulfate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

134−31−6 : 8−Hydroxyquinoline sulfate 

 Agonist: 0.014 Antagonist: 0.0012

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

134523−03−8 : Atorvastatin calcium 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

134523−03−8 : Atorvastatin calcium 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

134605−64−4 : Butafenacil 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

134605−64−4 : Butafenacil 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

134−62−3 : DEET 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

134−62−3 : DEET 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13463−41−7 : Zinc pyrithione 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13463−41−7 : Zinc pyrithione 

 Agonist: 0 Antagonist: 0.33

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

135080−03−4 : CP−100829 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

135080−03−4 : CP−100829 

 Agonist: 0 Antagonist: 0.02

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

135158−54−2 : Acibenzolar−S−methyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

135158−54−2 : Acibenzolar−S−methyl 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

135−19−3 : 2−Naphthalenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

135−19−3 : 2−Naphthalenol 

 Agonist: 0.15 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

135−20−6 : Cupferron 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

135−20−6 : Cupferron 

 Agonist: 0.018 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

135410−20−7 : Acetamiprid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

135410−20−7 : Acetamiprid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

136−45−8 : Dipropyl pyridine−2,5−dicarboxylate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

136−45−8 : Dipropyl pyridine−2,5−dicarboxylate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

136−60−7 : Butyl benzoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

136−60−7 : Butyl benzoate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13674−84−5 : Tris(2−chloroisopropyl)phosphate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13674−84−5 : Tris(2−chloroisopropyl)phosphate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13674−87−8 : Tris(1,3−dichloro−2−propyl)phosphate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13674−87−8 : Tris(1,3−dichloro−2−propyl)phosphate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

136−77−6 : 4−Hexylresorcinol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

136−77−6 : 4−Hexylresorcinol 

 Agonist: 0.063 Antagonist: 0.011

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13680−35−8 : 4,4'−Methylenebis(2,6−diethylaniline) 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13680−35−8 : 4,4'−Methylenebis(2,6−diethylaniline) 

 Agonist: 0 Antagonist: 0.063

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13684−56−5 : Desmedipham 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13684−56−5 : Desmedipham 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13684−63−4 : Phenmedipham 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13684−63−4 : Phenmedipham 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

137−26−8 : Thiram 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

137−26−8 : Thiram 

 Agonist: 0.0052 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

137−30−4 : Ziram 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

137−30−4 : Ziram 

 Agonist: 0 Antagonist: 0.043

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

137−42−8 : Metam−sodium 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

137−42−8 : Metam−sodium 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13755−29−8 : Sodium tetrafluoroborate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13755−29−8 : Sodium tetrafluoroborate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

137−66−6 : Ascorbyl palmitate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

137−66−6 : Ascorbyl palmitate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

138−22−7 : Butyl lactate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

138−22−7 : Butyl lactate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

138261−41−3 : Imidacloprid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

138261−41−3 : Imidacloprid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13826−35−2 : 3−Phenoxybenzenemethanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13826−35−2 : 3−Phenoxybenzenemethanol 

 Agonist: 0.093 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

138−86−3 : Limonene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

138−86−3 : Limonene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

139−02−6 : Sodium phenolate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

139−02−6 : Sodium phenolate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

139−13−9 : Nitrilotriacetic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

139−13−9 : Nitrilotriacetic acid 

 Agonist: 0.022 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

139149−55−6 : SB202235 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

139149−55−6 : SB202235 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

139290−65−6 : Volinanserin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

139290−65−6 : Volinanserin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

139340−56−0 : Darbufelone mesylate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

139340−56−0 : Darbufelone mesylate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

139−40−2 : Propazine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

139−40−2 : Propazine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

139−87−7 : Ethyl diethanolamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

139−87−7 : Ethyl diethanolamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

139−88−8 : 7−Ethyl−2−methyl−4−undecanolsulfate, sodium salt 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

139−88−8 : 7−Ethyl−2−methyl−4−undecanolsulfate, sodium salt 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

139−96−8 : Dodecyl sulfate triethanolamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

139−96−8 : Dodecyl sulfate triethanolamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

140−08−9 : Tris(2−chloroethyl) phosphite 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

140−08−9 : Tris(2−chloroethyl) phosphite 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

140−10−3 : Cinnamic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

140−10−3 : Cinnamic acid 

 Agonist: 0.11 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

140−11−4 : Benzyl acetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

140−11−4 : Benzyl acetate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1401−55−4 : Tannic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1401−55−4 : Tannic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

140−31−8 : 1−(2−Aminoethyl)piperazine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

140−31−8 : 1−(2−Aminoethyl)piperazine 

 Agonist: 0.0065 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

140−38−5 : 4−Chlorophenylurea 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

140−38−5 : 4−Chlorophenylurea 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

140−56−7 : Fenaminosulf 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

140−56−7 : Fenaminosulf 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

140−64−7 : Pentamidine isethionate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

140−64−7 : Pentamidine isethionate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

140−66−9 : 4−(1,1,3,3−Tetramethylbutyl)phenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

140−66−9 : 4−(1,1,3,3−Tetramethylbutyl)phenol 

 Agonist: 0.56 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

140−67−0 : Estragole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

140−67−0 : Estragole 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

140−95−4 : Dimethylolurea 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

140−95−4 : Dimethylolurea 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

141−04−8 : Diisobutyl adipate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

141−04−8 : Diisobutyl adipate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

141112−29−0 : Isoxaflutole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

141112−29−0 : Isoxaflutole 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

141−22−0 : 9−Octadecenoic acid, 12−hydroxy−, (9Z,12R)− 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

141−22−0 : 9−Octadecenoic acid, 12−hydroxy−, (9Z,12R)− 

 Agonist: 0 Antagonist: 0.028

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

141−32−2 : Butyl acrylate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

141−32−2 : Butyl acrylate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

141−43−5 : Ethanolamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

141−43−5 : Ethanolamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

141517−21−7 : Trifloxystrobin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

141517−21−7 : Trifloxystrobin 

 Agonist: 0 Antagonist: 0.00013

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

141−66−2 : Dicrotophos 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

141−66−2 : Dicrotophos 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

141−79−7 : 4−Methylpent−3−en−2−one 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

141−79−7 : 4−Methylpent−3−en−2−one 

 Agonist: 0.14 Antagonist: 0.051

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

142−04−1 : Aniline hydrochloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

142−04−1 : Aniline hydrochloride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

142−16−5 : Bis(2−ethylhexyl) maleate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

142−16−5 : Bis(2−ethylhexyl) maleate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

142−18−7 : 1−Monolaurin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

142−18−7 : 1−Monolaurin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

142−31−4 : Sodium octyl sulfate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

142−31−4 : Sodium octyl sulfate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

14233−37−5 : 1,4−Bis(N−isopropylamino)anthraquinone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

14233−37−5 : 1,4−Bis(N−isopropylamino)anthraquinone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

142459−58−3 : Flufenacet 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

142459−58−3 : Flufenacet 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

142−62−1 : Hexanoic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

142−62−1 : Hexanoic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

142−87−0 : Sodium decyl sulfate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

142−87−0 : Sodium decyl sulfate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

143−07−7 : Dodecanoic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

143−07−7 : Dodecanoic acid 

 Agonist: 0 Antagonist: 0.013

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

143−08−8 : 1−Nonanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

143−08−8 : 1−Nonanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

143−22−6 : 2−[2−(2−Butoxyethoxy)ethoxy]ethanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

143−22−6 : 2−[2−(2−Butoxyethoxy)ethoxy]ethanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

143390−89−0 : Kresoxim−methyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

143390−89−0 : Kresoxim−methyl 

 Agonist: 0.01 Antagonist: 0.075

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1434−54−4 : Pregnenolone carbonitrile 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1434−54−4 : Pregnenolone carbonitrile 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

143−50−0 : Kepone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

143−50−0 : Kepone 

 Agonist: 0.23 Antagonist: 0.029

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

14351−66−7 : Sodium abietate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

14351−66−7 : Sodium abietate 

 Agonist: 0.0022 Antagonist: 0.017

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

14371−10−9 : (2E)−3−Phenylprop−2−enal 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

14371−10−9 : (2E)−3−Phenylprop−2−enal 

 Agonist: 0.013 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

143−74−8 : Phenol red 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

143−74−8 : Phenol red 

 Agonist: 0.04 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

144−49−0 : Fluoroacetic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

144−49−0 : Fluoroacetic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

144550−36−7 : Iodosulfuron−methyl−sodium 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

144550−36−7 : Iodosulfuron−methyl−sodium 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1445−75−6 : Diisopropyl methylphosphonate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1445−75−6 : Diisopropyl methylphosphonate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

144−62−7 : Oxalic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

144−62−7 : Oxalic acid 

 Agonist: 0.017 Antagonist: 0.044

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

145701−21−9 : Diclosulam 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

145701−21−9 : Diclosulam 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

145−73−3 : Endothal 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

145−73−3 : Endothal 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

145742−28−5 : CP−122721 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

145742−28−5 : CP−122721 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1459−93−4 : Dimethyl isophthalate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1459−93−4 : Dimethyl isophthalate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1461−22−9 : Tributyltin chloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1461−22−9 : Tributyltin chloride 

 Agonist: 0 Antagonist: 0.072

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1461−25−2 : Tetrabutyltin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1461−25−2 : Tetrabutyltin 

 Agonist: 0 Antagonist: 0.007

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

147−24−0 : Diphenhydramine hydrochloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

147−24−0 : Diphenhydramine hydrochloride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

14765−30−1 : 2−sec−Butylcyclohexanone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

14765−30−1 : 2−sec−Butylcyclohexanone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1477−55−0 : 1,3−Benzenedimethanamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1477−55−0 : 1,3−Benzenedimethanamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

147−81−9 : Arabinose 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

147−81−9 : Arabinose 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1478−61−1 : Bisphenol AF 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1478−61−1 : Bisphenol AF 

 Agonist: 0.82 Antagonist: 0.0038

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

14816−18−3 : Phoxim 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

14816−18−3 : Phoxim 

 Agonist: 0.19 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

148−24−3 : 8−Hydroxyquinoline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

148−24−3 : 8−Hydroxyquinoline 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

148477−71−8 : Spirodiclofen 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

148477−71−8 : Spirodiclofen 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

148−79−8 : Thiabendazole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

148−79−8 : Thiabendazole 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1490−04−6 : Menthol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1490−04−6 : Menthol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

14901−07−6 : 4−(2,6,6−Trimethyl−cyclohex−1−enyl)−but−3−en−2−one 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

14901−07−6 : 4−(2,6,6−Trimethyl−cyclohex−1−enyl)−but−3−en−2−one 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

149062−75−9 : PharmaGSID_47259 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

149062−75−9 : PharmaGSID_47259 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

149−30−4 : 2−Mercaptobenzothiazole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

149−30−4 : 2−Mercaptobenzothiazole 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

149−57−5 : 2−Ethylhexanoic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

149−57−5 : 2−Ethylhexanoic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

149877−41−8 : Bifenazate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

149877−41−8 : Bifenazate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

149979−41−9 : Tepraloxydim 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

149979−41−9 : Tepraloxydim 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

150−13−0 : 4−Aminobenzoic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

150−13−0 : 4−Aminobenzoic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

15046−75−0 : Sodium 2−methylbenzenesulfonate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

15046−75−0 : Sodium 2−methylbenzenesulfonate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

150−68−5 : Monuron 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

150−68−5 : Monuron 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

150−76−5 : 4−Methoxyphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

150−76−5 : 4−Methoxyphenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

150−78−7 : Hydroquinone dimethyl ether 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

150−78−7 : Hydroquinone dimethyl ether 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

151−05−3 : Dimethylbenzylcarbinyl acetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

151−05−3 : Dimethylbenzylcarbinyl acetate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

151−21−3 : Sodium dodecyl sulfate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

151−21−3 : Sodium dodecyl sulfate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

15214−89−8 : 2−Acrylamido−2−methyl−1−propanesulfonic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

15214−89−8 : 2−Acrylamido−2−methyl−1−propanesulfonic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

15299−99−7 : Napropamide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

15299−99−7 : Napropamide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

15307−79−6 : Diclofenac sodium 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

15307−79−6 : Diclofenac sodium 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

15310−01−7 : Benodanil 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

15310−01−7 : Benodanil 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

153233−91−1 : Etoxazole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

153233−91−1 : Etoxazole 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

153719−23−4 : Thiamethoxam 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

153719−23−4 : Thiamethoxam 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1541−81−7 : 4−Dodecylmorpholine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1541−81−7 : 4−Dodecylmorpholine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

154−42−7 : 6−Thioguanine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

154−42−7 : 6−Thioguanine 

 Agonist: 0 Antagonist: 0.00013

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

15499−27−1 : 4−Butylchlorobenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

15499−27−1 : 4−Butylchlorobenzene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

155569−91−8 : Emamectin benzoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

155569−91−8 : Emamectin benzoate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1559−34−8 : 3,6,9,12−Tetraoxahexadecan−1−ol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1559−34−8 : 3,6,9,12−Tetraoxahexadecan−1−ol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1559−35−9 : 2−(2−Ethylhexyloxy)ethanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1559−35−9 : 2−(2−Ethylhexyloxy)ethanol 

 Agonist: 6e−07 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

155990−20−8 : SR271425 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

155990−20−8 : SR271425 

 Agonist: 0.044 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

156052−68−5 : Zoxamide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

156052−68−5 : Zoxamide 

 Agonist: 0 Antagonist: 0.025

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

156−10−5 : 4−Nitrosodiphenylamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

156−10−5 : 4−Nitrosodiphenylamine 

 Agonist: 0.035 Antagonist: 8e−04

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1563−38−8 : 2,3−Dihydro−2,2−dimethyl−7−benzofuranol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1563−38−8 : 2,3−Dihydro−2,2−dimethyl−7−benzofuranol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1563−66−2 : Carbofuran 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1563−66−2 : Carbofuran 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

156−43−4 : 4−Ethoxyaniline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

156−43−4 : 4−Ethoxyaniline 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

156−60−5 : (E)−1,2−Dichloroethylene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

156−60−5 : (E)−1,2−Dichloroethylene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1569−01−3 : 1−Propoxy−2−propanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1569−01−3 : 1−Propoxy−2−propanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1569−02−4 : 1−Ethoxy−2−propanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1569−02−4 : 1−Ethoxy−2−propanol 

 Agonist: 0.00084 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1570−64−5 : 4−Chloro−2−methylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1570−64−5 : 4−Chloro−2−methylphenol 

 Agonist: 0.019 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

15708−41−5 : Ethylenediaminetetraacetic acid ferric sodium salt 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

15708−41−5 : Ethylenediaminetetraacetic acid ferric sodium salt 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

158081−99−3 : CP−105696 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

158081−99−3 : CP−105696 

 Agonist: 0 Antagonist: 0.025

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1582−09−8 : Trifluralin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1582−09−8 : Trifluralin 

 Agonist: 0.027 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

159138−81−5 : Cariporide mesylate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

159138−81−5 : Cariporide mesylate 

 Agonist: 0.014 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1596−84−5 : Daminozide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1596−84−5 : Daminozide 

 Agonist: 0.049 Antagonist: 0.00084

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

15972−60−8 : Alachlor 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

15972−60−8 : Alachlor 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

16079−88−2 : Bromo−3−chloro−5,5−dimethylhydantoin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

16079−88−2 : Bromo−3−chloro−5,5−dimethylhydantoin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1610−18−0 : Prometon 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1610−18−0 : Prometon 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

161050−58−4 : Methoxyfenozide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

161050−58−4 : Methoxyfenozide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

161326−34−7 : Fenamidone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

161326−34−7 : Fenamidone 

 Agonist: 0.017 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

16219−75−3 : 5−Ethylidene−2−norbornene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

16219−75−3 : 5−Ethylidene−2−norbornene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1625−91−8 : 4,4'−Di−tert−butylbiphenyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1625−91−8 : 4,4'−Di−tert−butylbiphenyl 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

162706−14−1 : UK−156819 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

162706−14−1 : UK−156819 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1632−73−1 : Fenchol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1632−73−1 : Fenchol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1634−78−2 : Malaoxon 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1634−78−2 : Malaoxon 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

163520−33−0 : Isoxadifen−ethyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

163520−33−0 : Isoxadifen−ethyl 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1638−22−8 : 4−Butylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1638−22−8 : 4−Butylphenol 

 Agonist: 0.14 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

16423−68−0 : FD&C Red 3 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

16423−68−0 : FD&C Red 3 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1646−75−9 : Aldicarb oxime 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1646−75−9 : Aldicarb oxime 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1646−87−3 : Aldicarb sulfoxide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1646−87−3 : Aldicarb sulfoxide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1646−88−4 : Aldoxycarb 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1646−88−4 : Aldoxycarb 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

165252−70−0 : Dinotefuran 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

165252−70−0 : Dinotefuran 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

16587−71−6 : 4−(tert−Pentyl)−cyclohexanone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

16587−71−6 : 4−(tert−Pentyl)−cyclohexanone 

 Agonist: 0.04 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

166412−78−8 : Diisononyl cyclohexane−1,2−dicarboxylate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

166412−78−8 : Diisononyl cyclohexane−1,2−dicarboxylate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

16672−87−0 : Ethephon 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

16672−87−0 : Ethephon 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1671−75−6 : Heptanophenone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1671−75−6 : Heptanophenone 

 Agonist: 0.0051 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

16752−77−5 : Methomyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

16752−77−5 : Methomyl 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1675−54−3 : Bisphenol A diglycidyl ether 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1675−54−3 : Bisphenol A diglycidyl ether 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

16893−85−9 : Sodium hexafluorosilicate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

16893−85−9 : Sodium hexafluorosilicate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1689−84−5 : Bromoxynil 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1689−84−5 : Bromoxynil 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

169590−42−5 : Celecoxib 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

169590−42−5 : Celecoxib 

 Agonist: 0 Antagonist: 0.023

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1698−60−8 : Chloridazon 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1698−60−8 : Chloridazon 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1702−17−6 : Clopyralid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1702−17−6 : Clopyralid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

171866−31−2 : CP−283097 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

171866−31−2 : CP−283097 

 Agonist: 0.017 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1724−39−6 : Cyclododecanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1724−39−6 : Cyclododecanol 

 Agonist: 0.04 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

173584−44−6 : Indoxacarb 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

173584−44−6 : Indoxacarb 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

17372−87−1 : Eosin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

17372−87−1 : Eosin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1742−14−9 : 1,1−Bis(3,4−dimethylphenyl)ethane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1742−14−9 : 1,1−Bis(3,4−dimethylphenyl)ethane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

17465−86−0 : gamma−Cyclodextrin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

17465−86−0 : gamma−Cyclodextrin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

175013−18−0 : Pyraclostrobin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

175013−18−0 : Pyraclostrobin 

 Agonist: 0 Antagonist: 0.00067

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1760−24−3 : N−[3−(Trimethoxysilyl)propyl]ethane−1,2−diamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1760−24−3 : N−[3−(Trimethoxysilyl)propyl]ethane−1,2−diamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1762−95−4 : Thiocyanic acid, ammonium salt 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1762−95−4 : Thiocyanic acid, ammonium salt 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1763−23−1 : PFOS 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1763−23−1 : PFOS 

 Agonist: 0.0012 Antagonist: 0.0034

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

17696−62−7 : Phenylparaben 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

17696−62−7 : Phenylparaben 

 Agonist: 0.37 Antagonist: 0.017

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

177785−47−6 : PharmaGSID_47261 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

177785−47−6 : PharmaGSID_47261 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

17796−82−6 : N−(Cyclohexylthio)phthalimide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

17796−82−6 : N−(Cyclohexylthio)phthalimide 

 Agonist: 0.00084 Antagonist: 0.0033

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

17804−35−2 : Benomyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

17804−35−2 : Benomyl 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

17924−92−4 : Zearalenone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

17924−92−4 : Zearalenone 

 Agonist: 0.89 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

179465−71−5 : CJ−013790 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

179465−71−5 : CJ−013790 

 Agonist: 0.02 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

180084−01−9 : SB236057A 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

180084−01−9 : SB236057A 

 Agonist: 0 Antagonist: 0.038

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1806−26−4 : 4−Octylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1806−26−4 : 4−Octylphenol 

 Agonist: 0.15 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

181274−15−7 : Propoxycarbazone−sodium 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

181274−15−7 : Propoxycarbazone−sodium 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

181274−17−9 : Flucarbazone−sodium 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

181274−17−9 : Flucarbazone−sodium 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

181640−09−5 : SR144190 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

181640−09−5 : SR144190 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

18172−67−3 : (−)−beta−Pinene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

18172−67−3 : (−)−beta−Pinene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1825−21−4 : Pentachloroanisole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1825−21−4 : Pentachloroanisole 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1836−75−5 : Nitrofen 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1836−75−5 : Nitrofen 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1843−05−6 : Octabenzone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1843−05−6 : Octabenzone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

184653−84−7 : Carabersat 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

184653−84−7 : Carabersat 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1861−32−1 : Chlorthal−dimethyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1861−32−1 : Chlorthal−dimethyl 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1861−40−1 : Benfluralin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1861−40−1 : Benfluralin 

 Agonist: 0.041 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

186392−65−4 : Ingliforib 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

186392−65−4 : Ingliforib 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1873−88−7 : 1,1,1,3,5,5,5−Heptamethyltrisiloxane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1873−88−7 : 1,1,1,3,5,5,5−Heptamethyltrisiloxane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

188425−85−6 : Boscalid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

188425−85−6 : Boscalid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

188489−07−8 : Flufenpyr−ethyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

188489−07−8 : Flufenpyr−ethyl 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

189003−92−7 : Trelanserin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

189003−92−7 : Trelanserin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

18924−66−8 : 2,2'−(Tetradecylimino)diethanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

18924−66−8 : 2,2'−(Tetradecylimino)diethanol 

 Agonist: 4e−05 Antagonist: 0.086

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1897−45−6 : Chlorothalonil 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1897−45−6 : Chlorothalonil 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

18979−55−0 : 4−(Hexyloxy)phenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

18979−55−0 : 4−(Hexyloxy)phenol 

 Agonist: 0.23 Antagonist: 0.0038

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

19044−88−3 : Oryzalin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

19044−88−3 : Oryzalin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1907−65−9 : N−Butyl−p−toluenesulfonamide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1907−65−9 : N−Butyl−p−toluenesulfonamide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1912−24−9 : Atrazine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1912−24−9 : Atrazine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1918−00−9 : Dicamba 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1918−00−9 : Dicamba 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1918−02−1 : Picloram 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1918−02−1 : Picloram 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1918−16−7 : Propachlor 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1918−16−7 : Propachlor 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1929−73−3 : 2,4−D−Butotyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1929−73−3 : 2,4−D−Butotyl 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1929−77−7 : Vernolate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1929−77−7 : Vernolate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1929−82−4 : Nitrapyrin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1929−82−4 : Nitrapyrin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1934−21−0 : FD&C Yellow 5 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1934−21−0 : FD&C Yellow 5 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1936−15−8 : C.I. Acid Orange 10 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1936−15−8 : C.I. Acid Orange 10 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

194098−25−4 : CP−409092 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

194098−25−4 : CP−409092 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1948−33−0 : tert−Butylhydroquinone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1948−33−0 : tert−Butylhydroquinone 

 Agonist: 0.0053 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

19666−30−9 : Oxadiazon 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

19666−30−9 : Oxadiazon 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

196808−45−4 : Farglitazar 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

196808−45−4 : Farglitazar 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

197077−55−7 : UK−333747 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

197077−55−7 : UK−333747 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

19774−82−4 : Amiodarone hydrochloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

19774−82−4 : Amiodarone hydrochloride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

19780−11−1 : (2−Dodecenyl)succinic anhydride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

19780−11−1 : (2−Dodecenyl)succinic anhydride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1987−50−4 : 4−Heptylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1987−50−4 : 4−Heptylphenol 

 Agonist: 0.15 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

199119−58−9 : Trifloxysulfuron−sodium 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

199119−58−9 : Trifloxysulfuron−sodium 

 Agonist: 0.003 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

199171−88−5 : CP−401387 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

199171−88−5 : CP−401387 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

199584−38−8 : 1−Methoxy−4−tert−pentylcyclohexane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

199584−38−8 : 1−Methoxy−4−tert−pentylcyclohexane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2008−41−5 : Butylate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2008−41−5 : Butylate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

200940−23−4 : SB243213A 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

200940−23−4 : SB243213A 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2016−57−1 : 1−Decanamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2016−57−1 : 1−Decanamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

20265−97−8 : 4−Methoxyaniline hydrochloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

20265−97−8 : 4−Methoxyaniline hydrochloride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2031−67−6 : Triethoxymethylsilane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2031−67−6 : Triethoxymethylsilane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

20325−40−0 : 3,3'−Dimethoxybenzidine dihydrochloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

20325−40−0 : 3,3'−Dimethoxybenzidine dihydrochloride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

203942−49−8 : UK−337312 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

203942−49−8 : UK−337312 

 Agonist: 0.0024 Antagonist: 0.011

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2043−57−4 : 1H,1H,2H,2H−Perfluorooctyl iodide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2043−57−4 : 1H,1H,2H,2H−Perfluorooctyl iodide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2044−64−6 : N,N−Dimethylacetoacetamide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2044−64−6 : N,N−Dimethylacetoacetamide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2058−46−0 : Oxytetracycline hydrochloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2058−46−0 : Oxytetracycline hydrochloride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2058−94−8 : Perfluoroundecanoic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2058−94−8 : Perfluoroundecanoic acid 

 Agonist: 0.0038 Antagonist: 0.013

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

205−99−2 : Benzo(b)fluoranthene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

205−99−2 : Benzo(b)fluoranthene 

 Agonist: 0.01 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

206−44−0 : Fluoranthene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

206−44−0 : Fluoranthene 

 Agonist: 0.01 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

207736−05−8 : CI−1029 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

207736−05−8 : CI−1029 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

20780−48−7 : 3,7−Dimethyloctan−3−yl acetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

20780−48−7 : 3,7−Dimethyloctan−3−yl acetate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2078−54−8 : Propofol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2078−54−8 : Propofol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

20830−75−5 : Digoxin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

20830−75−5 : Digoxin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

208−96−8 : Acenaphthylene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

208−96−8 : Acenaphthylene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2104−64−5 : EPN 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2104−64−5 : EPN 

 Agonist: 0.12 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

210631−68−8 : Topramezone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

210631−68−8 : Topramezone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

210826−40−7 : CP−456773 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

210826−40−7 : CP−456773 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

21087−64−9 : Metribuzin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

21087−64−9 : Metribuzin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

210880−92−5 : Clothianidin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

210880−92−5 : Clothianidin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2110−18−1 : 2−(3−Phenylpropyl)pyridine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2110−18−1 : 2−(3−Phenylpropyl)pyridine 

 Agonist: 0.017 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

21145−77−7 : 6−Acetyl−1,1,2,4,4,7−hexamethyltetralin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

21145−77−7 : 6−Acetyl−1,1,2,4,4,7−hexamethyltetralin 

 Agonist: 0.054 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2122−70−5 : Ethyl 1−naphthaleneacetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2122−70−5 : Ethyl 1−naphthaleneacetate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

21245−02−3 : 2−Ethylhexyl 4−(dimethylamino)benzoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

21245−02−3 : 2−Ethylhexyl 4−(dimethylamino)benzoate 

 Agonist: 0.0098 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2144−53−8 : Tridecafluorohexylethyl methacrylate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2144−53−8 : Tridecafluorohexylethyl methacrylate 

 Agonist: 0.01 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

214535−77−0 : CP−457677 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

214535−77−0 : CP−457677 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

215297−27−1 : UK−343664 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

215297−27−1 : UK−343664 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2155−70−6 : Tributyltin methacrylate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2155−70−6 : Tributyltin methacrylate 

 Agonist: 0 Antagonist: 0.083

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

21564−17−0 : 2−(Thiocyanomethylthio)benzothiazole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

21564−17−0 : 2−(Thiocyanomethylthio)benzothiazole 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2164−17−2 : Fluometuron 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2164−17−2 : Fluometuron 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

21662−09−9 : (4Z)−4−Decenal 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

21662−09−9 : (4Z)−4−Decenal 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

21725−46−2 : Cyanazine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

21725−46−2 : Cyanazine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2176−62−7 : Pentachloropyridine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2176−62−7 : Pentachloropyridine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

219714−96−2 : Penoxsulam 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

219714−96−2 : Penoxsulam 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

219790−72−4 : SB281832 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

219790−72−4 : SB281832 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

22047−49−0 : 2−Ethylhexyl octadecanoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

22047−49−0 : 2−Ethylhexyl octadecanoate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

220860−50−4 : CP−457920 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

220860−50−4 : CP−457920 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

221246−12−4 : Fandosentan potassium salt 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

221246−12−4 : Fandosentan potassium salt 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2212−67−1 : Molinate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2212−67−1 : Molinate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

221671−62−1 : SR146131 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

221671−62−1 : SR146131 

 Agonist: 0 Antagonist: 0.007

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

22224−92−6 : Fenamiphos 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

22224−92−6 : Fenamiphos 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

22248−79−9 : Z−Tetrachlorvinphos 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

22248−79−9 : Z−Tetrachlorvinphos 

 Agonist: 0 Antagonist: 7.7e−05

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

22260−51−1 : Bromocriptine mesylate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

22260−51−1 : Bromocriptine mesylate 

 Agonist: 0 Antagonist: 0.034

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2231−57−4 : Thiocarbazide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2231−57−4 : Thiocarbazide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2243−62−1 : 1,5−Naphthalenediamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2243−62−1 : 1,5−Naphthalenediamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2244−21−5 : Potassium dichloroisocyanurate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2244−21−5 : Potassium dichloroisocyanurate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

22781−23−3 : Bendiocarb 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

22781−23−3 : Bendiocarb 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

22839−47−0 : Aspartame 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

22839−47−0 : Aspartame 

 Agonist: 0.0044 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

22915−73−7 : Hexane−1,6−diyl dibenzoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

22915−73−7 : Hexane−1,6−diyl dibenzoate 

 Agonist: 0.0058 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

23031−36−9 : Prallethrin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

23031−36−9 : Prallethrin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2303−17−5 : Tri−allate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2303−17−5 : Tri−allate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

23089−26−1 : Levomenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

23089−26−1 : Levomenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

230954−09−3 : CP−544439 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

230954−09−3 : CP−544439 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2310−17−0 : Phosalone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2310−17−0 : Phosalone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

23103−98−2 : Pirimicarb 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

23103−98−2 : Pirimicarb 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2312−35−8 : Propargite 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2312−35−8 : Propargite 

 Agonist: 0 Antagonist: 0.00013

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

23135−22−0 : Oxamyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

23135−22−0 : Oxamyl 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

23184−66−9 : Butachlor 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

23184−66−9 : Butachlor 

 Agonist: 0 Antagonist: 0.0073

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2321−07−5 : Fluorescein 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2321−07−5 : Fluorescein 

 Agonist: 8e−04 Antagonist: 0.026

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

23386−52−9 : Dicyclohexyl sodium sulfosuccinate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

23386−52−9 : Dicyclohexyl sodium sulfosuccinate 

 Agonist: 0.00016 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

23422−53−9 : Formetanate hydrochloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

23422−53−9 : Formetanate hydrochloride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2353−45−9 : FD&C Green No. 3 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2353−45−9 : FD&C Green No. 3 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

23564−05−8 : Thiophanate−methyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

23564−05−8 : Thiophanate−methyl 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

23564−06−9 : Thiophanate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

23564−06−9 : Thiophanate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

23593−75−1 : Clotrimazole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

23593−75−1 : Clotrimazole 

 Agonist: 0 Antagonist: 0.0065

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

23779−32−0 : 1−[3−(Triethoxysilyl)propyl]urea 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

23779−32−0 : 1−[3−(Triethoxysilyl)propyl]urea 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2385−85−5 : Mirex 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2385−85−5 : Mirex 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2386−87−0 : UT−632 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2386−87−0 : UT−632 

 Agonist: 0.0052 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2390−60−5 : Basic Blue 7 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2390−60−5 : Basic Blue 7 

 Agonist: 0 Antagonist: 0.065

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2392−39−4 : Dexamethasone sodium phosphate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2392−39−4 : Dexamethasone sodium phosphate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

23950−58−5 : Propyzamide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

23950−58−5 : Propyzamide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2396−68−1 : 4−tert−Butylbenzenethiol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2396−68−1 : 4−tert−Butylbenzenethiol 

 Agonist: 0.022 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2409−55−4 : 2−tert−Butyl−4−methylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2409−55−4 : 2−tert−Butyl−4−methylphenol 

 Agonist: 0 Antagonist: 0.023

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

24157−81−1 : 2,6−Diisopropylnaphthalene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

24157−81−1 : 2,6−Diisopropylnaphthalene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

24169−02−6 : Econazole nitrate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

24169−02−6 : Econazole nitrate 

 Agonist: 0 Antagonist: 0.05

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2416−94−6 : 2,3,6−Trimethylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2416−94−6 : 2,3,6−Trimethylphenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2425−06−1 : Captafol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2425−06−1 : Captafol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2425−77−6 : 2−Hexyl−1−decanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2425−77−6 : 2−Hexyl−1−decanol 

 Agonist: 0.0032 Antagonist: 0.0081

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2426−08−6 : Butyl glycidyl ether 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2426−08−6 : Butyl glycidyl ether 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

24307−26−4 : Mepiquat chloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

24307−26−4 : Mepiquat chloride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2432−87−3 : Dioctyl succinate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2432−87−3 : Dioctyl succinate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2433−14−9 : 4−Cyclohexylcyclohexanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2433−14−9 : 4−Cyclohexylcyclohexanol 

 Agonist: 0.037 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2440−22−4 : 2−(2H−Benzotriazol−2−yl)−4−methylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2440−22−4 : 2−(2H−Benzotriazol−2−yl)−4−methylphenol 

 Agonist: 0.083 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2445−77−4 : 2−Methylbutyl isovalerate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2445−77−4 : 2−Methylbutyl isovalerate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2451−62−9 : Triglycidyl isocyanurate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2451−62−9 : Triglycidyl isocyanurate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

24549−06−2 : 2−Ethyl−6−methylaniline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

24549−06−2 : 2−Ethyl−6−methylaniline 

 Agonist: 0.0088 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2457−01−4 : Barium bis(2−ethylhexanoate) 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2457−01−4 : Barium bis(2−ethylhexanoate) 

 Agonist: 0.024 Antagonist: 0.06

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

24602−86−6 : Tridemorph 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

24602−86−6 : Tridemorph 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2465−27−2 : Auramine hydrochloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2465−27−2 : Auramine hydrochloride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2467−02−9 : Bisphenol F 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2467−02−9 : Bisphenol F 

 Agonist: 0.046 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

24800−44−0 : Tripropylene glycol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

24800−44−0 : Tripropylene glycol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

24851−98−7 : Methyl dihydrojasmonate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

24851−98−7 : Methyl dihydrojasmonate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2491−38−5 : 2−Bromo−4−hydroxyacetophenone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2491−38−5 : 2−Bromo−4−hydroxyacetophenone 

 Agonist: 0.022 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2492−26−4 : Sodium 2−mercaptobenzothiolate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2492−26−4 : Sodium 2−mercaptobenzothiolate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

249296−43−3 : CJ−013610 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

249296−43−3 : CJ−013610 

 Agonist: 0 Antagonist: 0.055

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

25057−89−0 : Bentazone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

25057−89−0 : Bentazone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

25155−18−4 : Methylbenzethonium chloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

25155−18−4 : Methylbenzethonium chloride 

 Agonist: 0.017 Antagonist: 0.11

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

25155−30−0 : Sodium dodecylbenzenesulfonate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

25155−30−0 : Sodium dodecylbenzenesulfonate 

 Agonist: 0 Antagonist: 0.016

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

25168−05−2 : Chlorotoluene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

25168−05−2 : Chlorotoluene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

25265−71−8 : Dipropylene glycol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

25265−71−8 : Dipropylene glycol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2528−16−7 : Monobenzyl phthalate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2528−16−7 : Monobenzyl phthalate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

25322−69−4 : Polypropylene glycol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

25322−69−4 : Polypropylene glycol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

253450−09−8 : Besonprodil 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

253450−09−8 : Besonprodil 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

25360−10−5 : tert−Nonanethiol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

25360−10−5 : tert−Nonanethiol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

25496−72−4 : Glyceryl monooleate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

25496−72−4 : Glyceryl monooleate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

25498−49−1 : Tripropylene glycol monomethyl ether 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

25498−49−1 : Tripropylene glycol monomethyl ether 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2550−40−5 : Dicyclohexyl disulfide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2550−40−5 : Dicyclohexyl disulfide 

 Agonist: 0.014 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2554−06−5 : 1,3,5,7−Tetramethyl−1,3,5,7−tetravinylcyclotetrasiloxane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2554−06−5 : 1,3,5,7−Tetramethyl−1,3,5,7−tetravinylcyclotetrasiloxane 

 Agonist: 0.047 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

25550−98−5 : Diisodecylphenyl phosphite 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

25550−98−5 : Diisodecylphenyl phosphite 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

25606−41−1 : Propamocarb hydrochloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

25606−41−1 : Propamocarb hydrochloride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

25638−17−9 : Butylnaphthalenesulfonic acid sodium salt 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

25638−17−9 : Butylnaphthalenesulfonic acid sodium salt 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

25812−30−0 : Gemfibrozil 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

25812−30−0 : Gemfibrozil 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2593−15−9 : Etridiazole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2593−15−9 : Etridiazole 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

25956−17−6 : Allura Red C.I.16035 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

25956−17−6 : Allura Red C.I.16035 

 Agonist: 0 Antagonist: 0.018

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

26002−80−2 : Phenothrin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

26002−80−2 : Phenothrin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

26027−38−3 : Polyoxyethylene(10)nonylphenyl ether 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

26027−38−3 : Polyoxyethylene(10)nonylphenyl ether 

 Agonist: 3e−05 Antagonist: 0.2

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

26040−51−7 : Bis(2−ethylhexyl) tetrabromophthalate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

26040−51−7 : Bis(2−ethylhexyl) tetrabromophthalate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2610−11−9 : C.I. Direct Red 81 disodium salt 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2610−11−9 : C.I. Direct Red 81 disodium salt 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

26172−55−4 : 5−Chloro−2−methyl−3(2H)−isothiazolone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

26172−55−4 : 5−Chloro−2−methyl−3(2H)−isothiazolone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

261947−38−0 : CP−532623 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

261947−38−0 : CP−532623 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

26225−79−6 : Ethofumesate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

26225−79−6 : Ethofumesate 

 Agonist: 0.0056 Antagonist: 0.0094

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

262376−75−0 : HMR1426 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

262376−75−0 : HMR1426 

 Agonist: 0.012 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

26264−06−2 : Calcium dodecylbenzene sulfonate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

26264−06−2 : Calcium dodecylbenzene sulfonate 

 Agonist: 0 Antagonist: 0.035

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2627−95−4 : 1,3−Divinyl−1,1,3,3−tetramethyl disiloxane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2627−95−4 : 1,3−Divinyl−1,1,3,3−tetramethyl disiloxane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2634−33−5 : 1,2−Benzisothiazolin−3−one 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2634−33−5 : 1,2−Benzisothiazolin−3−one 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

263553−33−9 : GW473178E methyl benzene sulphonic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

263553−33−9 : GW473178E methyl benzene sulphonic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

26402−26−6 : Glyceryl monooctanoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

26402−26−6 : Glyceryl monooctanoate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

26447−10−9 : Ammonium xylene sulfonate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

26447−10−9 : Ammonium xylene sulfonate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

264618−44−2 : SSR146977 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

264618−44−2 : SSR146977 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

26530−20−1 : Octhilinone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

26530−20−1 : Octhilinone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

26628−22−8 : Sodium azide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

26628−22−8 : Sodium azide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

26644−46−2 : Triforine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

26644−46−2 : Triforine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2675−77−6 : Chloroneb 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2675−77−6 : Chloroneb 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2687−25−4 : 2,3−Diaminotoluene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2687−25−4 : 2,3−Diaminotoluene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2687−94−7 : N−Octyl−2−pyrrolidone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2687−94−7 : N−Octyl−2−pyrrolidone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2687−96−9 : 1−Dodecyl−2−pyrrolidinone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2687−96−9 : 1−Dodecyl−2−pyrrolidinone 

 Agonist: 0 Antagonist: 0.00014

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

26896−20−8 : Neodecanoic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

26896−20−8 : Neodecanoic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2694−54−4 : Triprop−2−en−1−yl benzene−1,2,4−tricarboxylate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2694−54−4 : Triprop−2−en−1−yl benzene−1,2,4−tricarboxylate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2696−84−6 : 4−Propylaniline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2696−84−6 : 4−Propylaniline 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2702−72−9 : 2,4−D sodium salt 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2702−72−9 : 2,4−D sodium salt 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

27090−63−7 : N,N,N',N'−Tetrabutyl−1,6−hexanediamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

27090−63−7 : N,N,N',N'−Tetrabutyl−1,6−hexanediamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

27138−31−4 : Di(propylene glycol) dibenzoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

27138−31−4 : Di(propylene glycol) dibenzoate 

 Agonist: 0.018 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

27176−87−0 : Dodecylbenzenesulfonic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

27176−87−0 : Dodecylbenzenesulfonic acid 

 Agonist: 0.0019 Antagonist: 0.026

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

27178−16−1 : Diisodecyl hexanedioate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

27178−16−1 : Diisodecyl hexanedioate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

271−89−6 : 2,3−Benzofuran 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

271−89−6 : 2,3−Benzofuran 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

27193−86−8 : Dodecylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

27193−86−8 : Dodecylphenol 

 Agonist: 0.54 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

27253−33−4 : Calcium neodecanoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

27253−33−4 : Calcium neodecanoate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

27306−78−1 : Silwet L77 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

27306−78−1 : Silwet L77 

 Agonist: 0.00012 Antagonist: 0.092

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

27314−13−2 : Norflurazon 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

27314−13−2 : Norflurazon 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

27323−41−7 : Dodecylbenzene sulfonate triethanolamine (1:1) 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

27323−41−7 : Dodecylbenzene sulfonate triethanolamine (1:1) 

 Agonist: 0.0055 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

27344−41−8 : Disodium 4,4'−bis(2−sulfostyryl)biphenyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

27344−41−8 : Disodium 4,4'−bis(2−sulfostyryl)biphenyl 

 Agonist: 0.0051 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2756−56−1 : Isobornyl propanoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2756−56−1 : Isobornyl propanoate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2761−24−2 : Triethoxypentylsilane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2761−24−2 : Triethoxypentylsilane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2772−45−4 : 2,4−Bis(1−methyl−1−phenylethyl)phenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2772−45−4 : 2,4−Bis(1−methyl−1−phenylethyl)phenol 

 Agonist: 0.043 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2782−57−2 : Troclosene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2782−57−2 : Troclosene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2783−94−0 : FD&C Yellow 6 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2783−94−0 : FD&C Yellow 6 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2795−39−3 : PFOS−K 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2795−39−3 : PFOS−K 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

27955−94−8 : 4,4',4−Ethane−1,1,1−triyltriphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

27955−94−8 : 4,4',4−Ethane−1,1,1−triyltriphenol 

 Agonist: 0.44 Antagonist: 0.038

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2807−30−9 : 2−Propoxyethanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2807−30−9 : 2−Propoxyethanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

28159−98−0 : Cybutryne 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

28159−98−0 : Cybutryne 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

28249−77−6 : Thiobencarb 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

28249−77−6 : Thiobencarb 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

283594−90−1 : Spiromesifen 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

283594−90−1 : Spiromesifen 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2835−95−2 : 5−Amino−2−methylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2835−95−2 : 5−Amino−2−methylphenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

28434−00−6 : S−Bioallethrin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

28434−00−6 : S−Bioallethrin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

28631−66−5 : C.I. Acid Blue 22 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

28631−66−5 : C.I. Acid Blue 22 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2870−32−8 : C.I. Direct Yellow 12 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2870−32−8 : C.I. Direct Yellow 12 

 Agonist: 0 Antagonist: 0.00023

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

28804−88−8 : Dimethylnaphthalene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

28804−88−8 : Dimethylnaphthalene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

288104−79−0 : Surinabant 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

288104−79−0 : Surinabant 

 Agonist: 0.038 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

288−32−4 : Imidazole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

288−32−4 : Imidazole 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

288−88−0 : 1H−1,2,4−Triazole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

288−88−0 : 1H−1,2,4−Triazole 

 Agonist: 0.00022 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2893−78−9 : Sodium dichloroisocyanurate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2893−78−9 : Sodium dichloroisocyanurate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

289716−94−5 : CP−607366 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

289716−94−5 : CP−607366 

 Agonist: 0 Antagonist: 0.005

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

290352−28−2 : CP−634384 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

290352−28−2 : CP−634384 

 Agonist: 0.0052 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

29091−21−2 : Prodiamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

29091−21−2 : Prodiamine 

 Agonist: 0.015 Antagonist: 0.08

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

29122−68−7 : Atenolol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

29122−68−7 : Atenolol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

291305−06−1 : UK−373911 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

291305−06−1 : UK−373911 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2917−73−9 : Dibutyl nonanedioate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2917−73−9 : Dibutyl nonanedioate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2919−66−6 : Melengestrol acetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2919−66−6 : Melengestrol acetate 

 Agonist: 0.098 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2921−88−2 : Chlorpyrifos 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2921−88−2 : Chlorpyrifos 

 Agonist: 0.032 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

29232−93−7 : Pirimiphos−methyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

29232−93−7 : Pirimiphos−methyl 

 Agonist: 0.038 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2934−05−6 : 2,4−Diisopropylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2934−05−6 : 2,4−Diisopropylphenol 

 Agonist: 0.011 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

29385−43−1 : Tolyltriazole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

29385−43−1 : Tolyltriazole 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

29387−86−8 : Propylene glycol monobutyl ether 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

29387−86−8 : Propylene glycol monobutyl ether 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

29420−49−3 : PFBS−K 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

29420−49−3 : PFBS−K 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2943−75−1 : Triethoxyoctylsilane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2943−75−1 : Triethoxyoctylsilane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

29590−42−9 : Isooctyl acrylate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

29590−42−9 : Isooctyl acrylate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2971−36−0 : 2,2−Bis(4−hydroxyphenyl)−1,1,1−trichloroethane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2971−36−0 : 2,2−Bis(4−hydroxyphenyl)−1,1,1−trichloroethane 

 Agonist: 0 Antagonist: 0.14

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

298−00−0 : Methyl parathion 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

298−00−0 : Methyl parathion 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

298−02−2 : Phorate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

298−02−2 : Phorate 

 Agonist: 0.02 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

298−04−4 : Disulfoton 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

298−04−4 : Disulfoton 

 Agonist: 0.027 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

298−07−7 : Bis(2−ethylhexyl) phosphate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

298−07−7 : Bis(2−ethylhexyl) phosphate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

298198−52−4 : SSR180711 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

298198−52−4 : SSR180711 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

29836−26−8 : Octyl beta−D−glucopyranoside 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

29836−26−8 : Octyl beta−D−glucopyranoside 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

298−46−4 : Carbamazepine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

298−46−4 : Carbamazepine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2996−92−1 : Trimethoxyphenylsilane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2996−92−1 : Trimethoxyphenylsilane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

300−76−5 : Naled 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

300−76−5 : Naled 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3025−30−7 : Ethyl (2E,4Z)−deca−2,4−dienoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3025−30−7 : Ethyl (2E,4Z)−deca−2,4−dienoate 

 Agonist: 0 Antagonist: 0.023

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3026−63−9 : Sodium tridecyl sulfate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3026−63−9 : Sodium tridecyl sulfate 

 Agonist: 0 Antagonist: 0.015

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

302−79−4 : trans−Retinoic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

302−79−4 : trans−Retinoic acid 

 Agonist: 1e−04 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3033−77−0 : N,N,N−Trimethyl(oxiran−2−yl)methanaminium chloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3033−77−0 : N,N,N−Trimethyl(oxiran−2−yl)methanaminium chloride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

30399−84−9 : Isooctadecanoic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

30399−84−9 : Isooctadecanoic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

30516−87−1 : 3'−Azido−3'−deoxythymidine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

30516−87−1 : 3'−Azido−3'−deoxythymidine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

30560−19−1 : Acephate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

30560−19−1 : Acephate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3056−17−5 : Stavudine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3056−17−5 : Stavudine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

307−24−4 : PFHxA 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

307−24−4 : PFHxA 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

309−00−2 : Aldrin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

309−00−2 : Aldrin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

311−45−5 : Paraoxon 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

311−45−5 : Paraoxon 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

31218−83−4 : Propetamphos 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

31218−83−4 : Propetamphos 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

313994−79−5 : MK−578 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

313994−79−5 : MK−578 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

314−40−9 : Bromacil 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

314−40−9 : Bromacil 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3147−75−9 : Octrizole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3147−75−9 : Octrizole 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

31519−22−9 : 1,4−Dihydroxy−2−naphthoic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

31519−22−9 : 1,4−Dihydroxy−2−naphthoic acid 

 Agonist: 0 Antagonist: 0.022

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3164−85−0 : Potassium 2−ethylhexanoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3164−85−0 : Potassium 2−ethylhexanoate 

 Agonist: 0.0072 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3194−55−6 : 1,2,5,6,9,10−Hexabromocyclododecane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3194−55−6 : 1,2,5,6,9,10−Hexabromocyclododecane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

319−85−7 : beta−Hexachlorocyclohexane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

319−85−7 : beta−Hexachlorocyclohexane 

 Agonist: 0.067 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

32388−55−9 : 1−Cedr−8−en−9−ylethanone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

32388−55−9 : 1−Cedr−8−en−9−ylethanone 

 Agonist: 0.097 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3268−49−3 : 3−(Methylthio)propanal 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3268−49−3 : 3−(Methylthio)propanal 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

32809−16−8 : Procymidone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

32809−16−8 : Procymidone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

328−84−7 : 1,2−Dichloro−4−(trifluoromethyl)benzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

328−84−7 : 1,2−Dichloro−4−(trifluoromethyl)benzene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3296−90−0 : 2,2−Bis(bromomethyl)−1,3−propanediol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3296−90−0 : 2,2−Bis(bromomethyl)−1,3−propanediol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

d glycerol monoester on 12−Hydroxystearic acid (85%); Fully acetylated glycerol monostearate represents (10%) 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

330198−91−9 : Fully acetylated glycerol monoester on 12−Hydroxystearic acid (85%); Fully acetylated glyce

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

330−54−1 : Diuron 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

330−54−1 : Diuron 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

330−55−2 : Linuron 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

330−55−2 : Linuron 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

33089−61−1 : Amitraz 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

33089−61−1 : Amitraz 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

331623−06−4 : MK−547 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

331623−06−4 : MK−547 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3319−31−1 : Tris(2−ethylhexyl) trimellitate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3319−31−1 : Tris(2−ethylhexyl) trimellitate 

 Agonist: 0.16 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

33228−44−3 : 4−Pentylaniline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

33228−44−3 : 4−Pentylaniline 

 Agonist: 0.029 Antagonist: 0.0046

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

33228−45−4 : 4−Hexylaniline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

33228−45−4 : 4−Hexylaniline 

 Agonist: 0.015 Antagonist: 0.05

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

333−41−5 : Diazinon 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

333−41−5 : Diazinon 

 Agonist: 0.044 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3337−71−1 : Asulam 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3337−71−1 : Asulam 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

334−48−5 : Decanoic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

334−48−5 : Decanoic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

335−67−1 : PFOA 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

335−67−1 : PFOA 

 Agonist: 0 Antagonist: 2.9e−06

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

335−76−2 : PFDA 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

335−76−2 : PFDA 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

33629−47−9 : Butralin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

33629−47−9 : Butralin 

 Agonist: 0.035 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

33703−08−1 : Hexanedioic acid, diisononyl ester 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

33703−08−1 : Hexanedioic acid, diisononyl ester 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3380−34−5 : Triclosan 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3380−34−5 : Triclosan 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

33820−53−0 : Isopropalin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

33820−53−0 : Isopropalin 

 Agonist: 0.015 Antagonist: 0.041

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3383−96−8 : Temephos 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3383−96−8 : Temephos 

 Agonist: 0.0025 Antagonist: 0.022

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3391−86−4 : 1−Octen−3−ol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3391−86−4 : 1−Octen−3−ol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

33956−49−9 : Codlelure 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

33956−49−9 : Codlelure 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

34014−18−1 : Tebuthiuron 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

34014−18−1 : Tebuthiuron 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

34256−82−1 : Acetochlor 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

34256−82−1 : Acetochlor 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

34451−19−9 : Butyl (2S)−2−hydroxypropanoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

34451−19−9 : Butyl (2S)−2−hydroxypropanoate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

344930−95−6 : SSR69071 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

344930−95−6 : SSR69071 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3452−97−9 : 3,5,5−Trimethyl−1−hexanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3452−97−9 : 3,5,5−Trimethyl−1−hexanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

34590−94−8 : Propanol, 1(or 2)−(2−methoxymethylethoxy)− 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

34590−94−8 : Propanol, 1(or 2)−(2−methoxymethylethoxy)− 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

349495−42−7 : PharmaGSID_47263 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

349495−42−7 : PharmaGSID_47263 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

35256−85−0 : Butam 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

35256−85−0 : Butam 

 Agonist: 0.08 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

353280−07−6 : CP−612372 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

353280−07−6 : CP−612372 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

35367−38−5 : Diflubenzuron 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

35367−38−5 : Diflubenzuron 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

35400−43−2 : Sulprofos 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

35400−43−2 : Sulprofos 

 Agonist: 0.028 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3547−33−9 : 2−Hydroxyethyl octyl sulfide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3547−33−9 : 2−Hydroxyethyl octyl sulfide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

35554−44−0 : Imazalil 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

35554−44−0 : Imazalil 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

35575−96−3 : Azamethiphos 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

35575−96−3 : Azamethiphos 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

35691−65−7 : 1,2−Dibromo−2,4−dicyanobutane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

35691−65−7 : 1,2−Dibromo−2,4−dicyanobutane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

361343−19−3 : Elzasonan 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

361343−19−3 : Elzasonan 

 Agonist: 0 Antagonist: 0.009

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

361377−29−9 : Fluoxastrobin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

361377−29−9 : Fluoxastrobin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3622−84−2 : N−Butylbenzenesulfonamide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3622−84−2 : N−Butylbenzenesulfonamide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3653−48−3 : MCPA−sodium 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3653−48−3 : MCPA−sodium 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

36631−30−8 : Triisodecyl trimellitate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

36631−30−8 : Triisodecyl trimellitate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

36653−82−4 : 1−Hexadecanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

36653−82−4 : 1−Hexadecanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

36734−19−7 : Iprodione 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

36734−19−7 : Iprodione 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3681−71−8 : (3Z)−3−Hexenyl acetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3681−71−8 : (3Z)−3−Hexenyl acetate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

368832−42−2 : CP−728663 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

368832−42−2 : CP−728663 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3691−35−8 : Chlorophacinone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3691−35−8 : Chlorophacinone 

 Agonist: 0 Antagonist: 0.031

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3734−33−6 : Denatonium benzoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3734−33−6 : Denatonium benzoate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3734−67−6 : C.I. Acid Red 1 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3734−67−6 : C.I. Acid Red 1 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3739−38−6 : 3−Phenoxybenzoic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3739−38−6 : 3−Phenoxybenzoic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

375−85−9 : Perfluoroheptanoic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

375−85−9 : Perfluoroheptanoic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

375−95−1 : PFNA 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

375−95−1 : PFNA 

 Agonist: 0.007 Antagonist: 0.02

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

37764−25−3 : Dichlormid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

37764−25−3 : Dichlormid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3811−04−9 : Potassium chlorate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3811−04−9 : Potassium chlorate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3811−73−2 : Sodium (2−pyridylthio)−N−oxide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3811−73−2 : Sodium (2−pyridylthio)−N−oxide 

 Agonist: 0 Antagonist: 0.019

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3825−26−1 : PFOA, ammonium salt 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3825−26−1 : PFOA, ammonium salt 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3844−45−9 : FD&C Blue No. 1 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3844−45−9 : FD&C Blue No. 1 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3855−32−1 : 2,6,10−Trimethyl−2,6,10−triazaundecane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3855−32−1 : 2,6,10−Trimethyl−2,6,10−triazaundecane 

 Agonist: 0.0049 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3871−99−6 : PFHS−K 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3871−99−6 : PFHS−K 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3913−02−8 : 2−Butyloctan−1−ol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3913−02−8 : 2−Butyloctan−1−ol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

39236−46−9 : Imidazolidinyl urea 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

39236−46−9 : Imidazolidinyl urea 

 Agonist: 0.0052 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3926−62−3 : Sodium chloroacetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

3926−62−3 : Sodium chloroacetate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

39300−45−3 : Dinocap 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

39300−45−3 : Dinocap 

 Agonist: 0 Antagonist: 0.046

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

39515−41−8 : Fenpropathrin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

39515−41−8 : Fenpropathrin 

 Agonist: 0.0092 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

39905−57−2 : 4−Hexyloxyaniline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

39905−57−2 : 4−Hexyloxyaniline 

 Agonist: 0.016 Antagonist: 0.003

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

402910−27−4 : UK−416244 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

402910−27−4 : UK−416244 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

40487−42−1 : Pendimethalin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

40487−42−1 : Pendimethalin 

 Agonist: 0.11 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

40649−36−3 : 4−Propylcyclohexanone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

40649−36−3 : 4−Propylcyclohexanone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4065−45−6 : Sulisobenzone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4065−45−6 : Sulisobenzone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4098−71−9 : Isophorone diisocyanate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4098−71−9 : Isophorone diisocyanate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4107−98−6 : N,N−Diisopropylaniline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4107−98−6 : N,N−Diisopropylaniline 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

41198−08−7 : Profenofos 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

41198−08−7 : Profenofos 

 Agonist: 0.0074 Antagonist: 0.014

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4130−42−1 : 2,6−Di−tert−butyl−4−ethylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4130−42−1 : 2,6−Di−tert−butyl−4−ethylphenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

41372−08−1 : Methyldopa sesquihydrate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

41372−08−1 : Methyldopa sesquihydrate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

41372−20−7 : Apomorphine hydrochloride hydrate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

41372−20−7 : Apomorphine hydrochloride hydrate 

 Agonist: 0.0071 Antagonist: 0.031

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

41481−66−7 : 4,4'−Sulfonylbis[2−(prop−2−en−1−yl)phenol] 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

41481−66−7 : 4,4'−Sulfonylbis[2−(prop−2−en−1−yl)phenol] 

 Agonist: 0.02 Antagonist: 0.038

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4151−50−2 : Sulfluramid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4151−50−2 : Sulfluramid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4180−23−8 : (E)−Anethole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4180−23−8 : (E)−Anethole 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

420−04−2 : Cyanamide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

420−04−2 : Cyanamide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

42509−80−8 : Isazofos 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

42509−80−8 : Isazofos 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

427−51−0 : Cyproterone acetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

427−51−0 : Cyproterone acetate 

 Agonist: 0.00028 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

42874−03−3 : Oxyfluorfen 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

42874−03−3 : Oxyfluorfen 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4291−63−8 : Cladribine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4291−63−8 : Cladribine 

 Agonist: 0.016 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

43121−43−3 : Triadimefon 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

43121−43−3 : Triadimefon 

 Agonist: 0.0095 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

43222−48−6 : Difenzoquat metilsulfate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

43222−48−6 : Difenzoquat metilsulfate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4342−36−3 : Tributyltin benzoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4342−36−3 : Tributyltin benzoate 

 Agonist: 0 Antagonist: 0.15

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4344−55−2 : 4−Butyloxyaniline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4344−55−2 : 4−Butyloxyaniline 

 Agonist: 0.011 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4376−18−5 : Monomethyl phthalate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4376−18−5 : Monomethyl phthalate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4376−20−9 : Mono(2−ethylhexyl) phthalate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4376−20−9 : Mono(2−ethylhexyl) phthalate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

439687−69−1 : Nelivaptan 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

439687−69−1 : Nelivaptan 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4418−26−2 : Sodium dehydroacetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4418−26−2 : Sodium dehydroacetate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4437−85−8 : Butylene carbonate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4437−85−8 : Butylene carbonate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

444610−91−7 : PharmaGSID_47315 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

444610−91−7 : PharmaGSID_47315 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4449−51−8 : Cyclopamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4449−51−8 : Cyclopamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

445295−04−5 : CP−671305 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

445295−04−5 : CP−671305 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4455−26−9 : N−Methyldioctylamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4455−26−9 : N−Methyldioctylamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

446−72−0 : Genistein 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

446−72−0 : Genistein 

 Agonist: 0.77 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4468−42−2 : 3−Phenylhexane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4468−42−2 : 3−Phenylhexane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

446−86−6 : Azathioprine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

446−86−6 : Azathioprine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

451−40−1 : 1,2−Diphenylethanone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

451−40−1 : 1,2−Diphenylethanone 

 Agonist: 0.035 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4548−53−2 : FD&C Red 4 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4548−53−2 : FD&C Red 4 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4553−62−2 : 2−Methylpentanedinitrile 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4553−62−2 : 2−Methylpentanedinitrile 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4−3 : Myristyltrimethylammonium chlorideN,N,N−Trimethyltetradecan−1−aminium chloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4574−04−3 : Myristyltrimethylammonium chlorideN,N,N−Trimethyltetradecan−1−amin

 Agonist: 5.5e−05 Antagonist: 0.043

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

460−00−4 : 1−Bromo−4−fluorobenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

460−00−4 : 1−Bromo−4−fluorobenzene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4602−84−0 : Farnesol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4602−84−0 : Farnesol 

 Agonist: 0.022 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

461023−63−2 : Aplaviroc hydrochloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

461023−63−2 : Aplaviroc hydrochloride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

461−58−5 : Cyanoguanidine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

461−58−5 : Cyanoguanidine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

463−40−1 : Linolenic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

463−40−1 : Linolenic acid 

 Agonist: 0.0018 Antagonist: 0.0056

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4638−48−6 : 5−Chlorosalicylanilide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4638−48−6 : 5−Chlorosalicylanilide 

 Agonist: 0 Antagonist: 0.026

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

464−49−3 : D−Camphor 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

464−49−3 : D−Camphor 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4707−47−5 : Methyl 2,4−dihydroxy−3,6−dimethylbenzoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4707−47−5 : Methyl 2,4−dihydroxy−3,6−dimethylbenzoate 

 Agonist: 0.015 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

470−82−6 : 1,8−Cineol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

470−82−6 : 1,8−Cineol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4712−55−4 : Diphenyl phosphite 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4712−55−4 : Diphenyl phosphite 

 Agonist: 0.16 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

473289−62−2 : Ilepatril 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

473289−62−2 : Ilepatril 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

474−86−2 : Equilin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

474−86−2 : Equilin 

 Agonist: 0.98 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

478149−53−0 : PHA−00543613 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

478149−53−0 : PHA−00543613 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

478263−98−8 : AVE3295 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

478263−98−8 : AVE3295 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

480−40−0 : Chrysin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

480−40−0 : Chrysin 

 Agonist: 0.16 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

480−63−7 : 2,4,6−Trimethylbenzoic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

480−63−7 : 2,4,6−Trimethylbenzoic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

484−17−3 : 9−Phenanthrol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

484−17−3 : 9−Phenanthrol 

 Agonist: 0 Antagonist: 0.031

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

486−56−6 : Cotinine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

486−56−6 : Cotinine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

486−66−8 : Daidzein 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

486−66−8 : Daidzein 

 Agonist: 0.62 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

487−06−9 : 5,7−Dimethoxy−2H−chromen−2−one 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

487−06−9 : 5,7−Dimethoxy−2H−chromen−2−one 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

489−01−0 : 2,6−Di−tert−butyl−4−methoxyphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

489−01−0 : 2,6−Di−tert−butyl−4−methoxyphenol 

 Agonist: 0.01 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4904−61−4 : 1,5,9−Cyclododecatriene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4904−61−4 : 1,5,9−Cyclododecatriene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

491−80−5 : Biochanin A 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

491−80−5 : Biochanin A 

 Agonist: 0.47 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

493−52−7 : Methyl red 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

493−52−7 : Methyl red 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4940−11−8 : 2−Ethyl−3−hydroxy−4H−pyran−4−one 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

4940−11−8 : 2−Ethyl−3−hydroxy−4H−pyran−4−one 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

49562−28−9 : Fenofibrate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

49562−28−9 : Fenofibrate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

496−46−8 : Glycoluril 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

496−46−8 : Glycoluril 

 Agonist: 0.035 Antagonist: 0.088

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

496−72−0 : 3,4−Diaminotoluene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

496−72−0 : 3,4−Diaminotoluene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

499−75−2 : Isopropyl−o−cresol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

499−75−2 : Isopropyl−o−cresol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

499−83−2 : 2,6−Pyridinedicarboxylic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

499−83−2 : 2,6−Pyridinedicarboxylic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

500−38−9 : Nordihydroguaiaretic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

500−38−9 : Nordihydroguaiaretic acid 

 Agonist: 0.18 Antagonist: 0.046

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

501027−49−2 : PD−0333941 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

501027−49−2 : PD−0333941 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−14−6 : Ergocalciferol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−14−6 : Ergocalciferol 

 Agonist: 0 Antagonist: 0.024

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−21−5 : Lactic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−21−5 : Lactic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−22−6 : Corticosterone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−22−6 : Corticosterone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−27−1 : Estriol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−27−1 : Estriol 

 Agonist: 0.96 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−28−2 : 17beta−Estradiol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−28−2 : 17beta−Estradiol 

 Agonist: 1 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−29−3 : p,p'−DDT 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−29−3 : p,p'−DDT 

 Agonist: 0.24 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−35−1 : Thalidomide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−35−1 : Thalidomide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−41−9 : Clomiphene citrate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−41−9 : Clomiphene citrate 

 Agonist: 0.031 Antagonist: 0.82

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50471−44−8 : Vinclozolin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50471−44−8 : Vinclozolin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−55−5 : Reserpine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−55−5 : Reserpine 

 Agonist: 0 Antagonist: 8.2e−09

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50594−66−6 : Acifluorfen 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50594−66−6 : Acifluorfen 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−65−7 : Niclosamide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−65−7 : Niclosamide 

 Agonist: 0 Antagonist: 0.00011

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−70−4 : D−Glucitol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−70−4 : D−Glucitol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−78−2 : Aspirin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−78−2 : Aspirin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−81−7 : L−Ascorbic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−81−7 : L−Ascorbic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50892−23−4 : Pirinixic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50892−23−4 : Pirinixic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

510−15−6 : Chlorobenzilate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

510−15−6 : Chlorobenzilate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

51−03−6 : Piperonyl butoxide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

51−03−6 : Piperonyl butoxide 

 Agonist: 0.0065 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

51−05−8 : Procaine hydrochloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

51−05−8 : Procaine hydrochloride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5116−94−9 : Monotridecyl phosphate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5116−94−9 : Monotridecyl phosphate 

 Agonist: 0 Antagonist: 0.016

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

51−21−8 : 5−Fluorouracil 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

51−21−8 : 5−Fluorouracil 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

51218−45−2 : Metolachlor 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

51218−45−2 : Metolachlor 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

51229−78−8 : Chloroallyl methenamine chloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

51229−78−8 : Chloroallyl methenamine chloride 

 Agonist: 0.0024 Antagonist: 0.006

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

51235−04−2 : Hexazinone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

51235−04−2 : Hexazinone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

51−24−1 : Tiratricol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

51−24−1 : Tiratricol 

 Agonist: 0.18 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

512−42−5 : Sodium methyl sulfate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

512−42−5 : Sodium methyl sulfate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

512−56−1 : Trimethyl phosphate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

512−56−1 : Trimethyl phosphate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

51−28−5 : 2,4−Dinitrophenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

51−28−5 : 2,4−Dinitrophenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

51−30−9 : Isoproterenol hydrochloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

51−30−9 : Isoproterenol hydrochloride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

51338−27−3 : Diclofop−methyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

51338−27−3 : Diclofop−methyl 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5137−55−3 : Methyltrioctylammonium chloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5137−55−3 : Methyltrioctylammonium chloride 

 Agonist: 0.0048 Antagonist: 0.04

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5138−18−1 : Sulfosuccinic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5138−18−1 : Sulfosuccinic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5146−66−7 : 2,6−Octadienenitrile, 3,7−dimethyl− 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5146−66−7 : 2,6−Octadienenitrile, 3,7−dimethyl− 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

51−52−5 : 6−Propyl−2−thiouracil 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

51−52−5 : 6−Propyl−2−thiouracil 

 Agonist: 0.12 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5153−25−3 : 2−Ethylhexylparaben 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5153−25−3 : 2−Ethylhexylparaben 

 Agonist: 0.51 Antagonist: 0.006

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

51580−86−0 : Sodium dichloro−s−triazinetrione dihydrate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

51580−86−0 : Sodium dichloro−s−triazinetrione dihydrate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

51630−58−1 : Fenvalerate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

51630−58−1 : Fenvalerate 

 Agonist: 0.0038 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

51632−16−7 : 1−(Bromomethyl)−3−phenoxybenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

51632−16−7 : 1−(Bromomethyl)−3−phenoxybenzene 

 Agonist: 0.082 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

51707−55−2 : Thidiazuron 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

51707−55−2 : Thidiazuron 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

51−79−6 : Urethane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

51−79−6 : Urethane 

 Agonist: 0.0014 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

52−01−7 : Spironolactone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

52−01−7 : Spironolactone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

520−18−3 : Kaempferol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

520−18−3 : Kaempferol 

 Agonist: 0.34 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

520−36−5 : Apigenin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

520−36−5 : Apigenin 

 Agonist: 0.43 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

520−45−6 : Dehydroacetic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

520−45−6 : Dehydroacetic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

521−18−6 : 5alpha−Dihydrotestosterone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

521−18−6 : 5alpha−Dihydrotestosterone 

 Agonist: 0.5 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5216−25−1 : 4−Chlorobenzotrichloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5216−25−1 : 4−Chlorobenzotrichloride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

52225−20−4 : dl−alpha−Tocopheryl acetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

52225−20−4 : dl−alpha−Tocopheryl acetate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

52315−07−8 : Cypermethrin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

52315−07−8 : Cypermethrin 

 Agonist: 0.0099 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5234−68−4 : Carboxin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5234−68−4 : Carboxin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

52−51−7 : Bronopol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

52−51−7 : Bronopol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

525−79−1 : Kinetin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

525−79−1 : Kinetin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

525−82−6 : Flavone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

525−82−6 : Flavone 

 Agonist: 0.034 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

52645−53−1 : Permethrin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

52645−53−1 : Permethrin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

526−75−0 : 2,3−Dimethylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

526−75−0 : 2,3−Dimethylphenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

52−68−6 : Trichlorfon 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

52−68−6 : Trichlorfon 

 Agonist: 0.064 Antagonist: 0.0033

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

527−60−6 : 2,4,6−Trimethylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

527−60−6 : 2,4,6−Trimethylphenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

527680−56−4 : PHA−00568487 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

527680−56−4 : PHA−00568487 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

52806−53−8 : Hydroxyflutamide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

52806−53−8 : Hydroxyflutamide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

528−29−0 : 1,2−Dinitrobenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

528−29−0 : 1,2−Dinitrobenzene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

52−86−8 : Haloperidol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

52−86−8 : Haloperidol 

 Agonist: 0.011 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

52918−63−5 : Deltamethrin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

52918−63−5 : Deltamethrin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

53−03−2 : Prednisone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

53−03−2 : Prednisone 

 Agonist: 0.059 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

53112−28−0 : Pyrimethanil 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

53112−28−0 : Pyrimethanil 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5315−79−7 : 1−Hydroxypyrene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5315−79−7 : 1−Hydroxypyrene 

 Agonist: 0.008 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

53−16−7 : Estrone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

53−16−7 : Estrone 

 Agonist: 0.99 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

53−19−0 : o,p'−DDD 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

53−19−0 : o,p'−DDD 

 Agonist: 0.32 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

532−02−5 : Sodium 2−naphthalenesulfonate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

532−02−5 : Sodium 2−naphthalenesulfonate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

53219−21−9 : 7−Octen−2−ol, 2−methyl−6−methylene−, dihydro deriv. 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

53219−21−9 : 7−Octen−2−ol, 2−methyl−6−methylene−, dihydro deriv. 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

532−27−4 : 2−Chloroacetophenone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

532−27−4 : 2−Chloroacetophenone 

 Agonist: 0.014 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

532−32−1 : Sodium benzoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

532−32−1 : Sodium benzoate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5329−14−6 : Sulfamic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5329−14−6 : Sulfamic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

533−23−3 : 2,4−D−ethyl ester 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

533−23−3 : 2,4−D−ethyl ester 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5333−42−6 : 2−Octyl−1−dodecanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5333−42−6 : 2−Octyl−1−dodecanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

533−74−4 : Dazomet 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

533−74−4 : Dazomet 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

534−13−4 : N,N'−Dimethylthiourea 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

534−13−4 : N,N'−Dimethylthiourea 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

53−43−0 : Dehydroepiandrosterone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

53−43−0 : Dehydroepiandrosterone 

 Agonist: 0.51 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

534−52−1 : 2−Methyl−4,6−dinitrophenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

534−52−1 : 2−Methyl−4,6−dinitrophenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5349−51−9 : 4−(2−Methylbutan−2−yl)cyclohexanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5349−51−9 : 4−(2−Methylbutan−2−yl)cyclohexanol 

 Agonist: 0.26 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

53−70−3 : Dibenz(a,h)anthracene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

53−70−3 : Dibenz(a,h)anthracene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

53−86−1 : Indomethacin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

53−86−1 : Indomethacin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

53894−23−8 : Triisononyl trimellitate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

53894−23−8 : Triisononyl trimellitate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5392−40−5 : 3,7−Dimethyl−2,6−octadienal 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5392−40−5 : 3,7−Dimethyl−2,6−octadienal 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

53939−28−9 : (Z)−11−Hexadecenal 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

53939−28−9 : (Z)−11−Hexadecenal 

 Agonist: 0.049 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5394−36−5 : 5−Ethyl−5−methylhydantoin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5394−36−5 : 5−Ethyl−5−methylhydantoin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

540−18−1 : Pentyl butyrate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

540−18−1 : Pentyl butyrate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5407−98−7 : Cyclobutyl phenyl ketone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5407−98−7 : Cyclobutyl phenyl ketone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

540−88−5 : tert−Butyl acetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

540−88−5 : tert−Butyl acetate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

541−02−6 : Decamethylcyclopentasiloxane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

541−02−6 : Decamethylcyclopentasiloxane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

54−11−5 : Nicotine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

54−11−5 : Nicotine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

541−73−1 : 1,3−Dichlorobenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

541−73−1 : 1,3−Dichlorobenzene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

542−92−7 : 1,3−Cyclopentadiene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

542−92−7 : 1,3−Cyclopentadiene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5437−45−6 : Benzyl bromoacetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5437−45−6 : Benzyl bromoacetate 

 Agonist: 0.0014 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

544−63−8 : Tetradecanoic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

544−63−8 : Tetradecanoic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

544−76−3 : Hexadecane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

544−76−3 : Hexadecane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

54593−83−8 : Chlorethoxyfos 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

54593−83−8 : Chlorethoxyfos 

 Agonist: 0.029 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

54−62−6 : 4−Aminofolic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

54−62−6 : 4−Aminofolic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

54−85−3 : Isoniazid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

54−85−3 : Isoniazid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

548−62−9 : Gentian Violet 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

548−62−9 : Gentian Violet 

 Agonist: 0 Antagonist: 5.3e−05

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

54965−24−1 : Tamoxifen citrate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

54965−24−1 : Tamoxifen citrate 

 Agonist: 0.019 Antagonist: 0.78

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

550−44−7 : N−Methylphthalimide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

550−44−7 : N−Methylphthalimide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

55−18−5 : N−Nitrosodiethylamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

55−18−5 : N−Nitrosodiethylamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

55219−65−3 : Triadimenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

55219−65−3 : Triadimenol 

 Agonist: 0.033 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

552−30−7 : Trimellitic anhydride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

552−30−7 : Trimellitic anhydride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

55283−68−6 : Ethalfluralin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

55283−68−6 : Ethalfluralin 

 Agonist: 0.039 Antagonist: 9.7e−08

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

55285−14−8 : Carbosulfan 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

55285−14−8 : Carbosulfan 

 Agonist: 0.01 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

55290−64−7 : Dimethipin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

55290−64−7 : Dimethipin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

553−26−4 : 4,4'−Bipyridine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

553−26−4 : 4,4'−Bipyridine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

55335−06−3 : Triclopyr 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

55335−06−3 : Triclopyr 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5536−61−8 : Sodium methacrylate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5536−61−8 : Sodium methacrylate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

553−70−8 : Magnesium dibenzoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

553−70−8 : Magnesium dibenzoate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

55−38−9 : Fenthion 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

55−38−9 : Fenthion 

 Agonist: 0.0072 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

55406−53−6 : 3−Iodo−2−propynyl−N−butylcarbamate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

55406−53−6 : 3−Iodo−2−propynyl−N−butylcarbamate 

 Agonist: 0 Antagonist: 0.02

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

55512−33−9 : Pyridate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

55512−33−9 : Pyridate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

55589−62−3 : Acesulfame potassium 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

55589−62−3 : Acesulfame potassium 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

556−52−5 : Glycidol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

556−52−5 : Glycidol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

556−61−6 : Methyl isothiocyanate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

556−61−6 : Methyl isothiocyanate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

556−67−2 : Octamethylcyclotetrasiloxane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

556−67−2 : Octamethylcyclotetrasiloxane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

55814−41−0 : Mepronil 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

55814−41−0 : Mepronil 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

55934−93−5 : Tripropylene glycol butyl ether 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

55934−93−5 : Tripropylene glycol butyl ether 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

55−98−1 : Busulfan 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

55−98−1 : Busulfan 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5598−13−0 : Chlorpyrifos−methyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5598−13−0 : Chlorpyrifos−methyl 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5598−15−2 : Chlorpyrifos oxon 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5598−15−2 : Chlorpyrifos oxon 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

56−04−2 : 6−Methyl−2−thiouracil 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

56−04−2 : 6−Methyl−2−thiouracil 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

563−12−2 : Ethion 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

563−12−2 : Ethion 

 Agonist: 0.14 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

56375−79−2 : N,N−Dibutyl−N−methylbutan−1−aminium chloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

56375−79−2 : N,N−Dibutyl−N−methylbutan−1−aminium chloride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

56−38−2 : Parathion 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

56−38−2 : Parathion 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

56−53−1 : Diethylstilbestrol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

56−53−1 : Diethylstilbestrol 

 Agonist: 1 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

56−55−3 : Benz(a)anthracene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

56−55−3 : Benz(a)anthracene 

 Agonist: 0.043 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

56−72−4 : Coumaphos 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

56−72−4 : Coumaphos 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

56−81−5 : Glycerol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

56−81−5 : Glycerol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

56−95−1 : Chlorhexidine diacetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

56−95−1 : Chlorhexidine diacetate 

 Agonist: 0.0023 Antagonist: 0.13

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5700−49−2 : 1,2−Ethanediamine dihydriodide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5700−49−2 : 1,2−Ethanediamine dihydriodide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−06−7 : Allyl isothiocyanate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−06−7 : Allyl isothiocyanate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−09−0 : Hexadecyltrimethylammonium bromide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−09−0 : Hexadecyltrimethylammonium bromide 

 Agonist: 4.7e−05 Antagonist: 0.1

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−10−3 : Hexadecanoic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−10−3 : Hexadecanoic acid 

 Agonist: 0.0033 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−11−4 : Octadecanoic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−11−4 : Octadecanoic acid 

 Agonist: 0.19 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−13−6 : Urea 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−13−6 : Urea 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−14−7 : 1,1−Dimethylhydrazine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−14−7 : 1,1−Dimethylhydrazine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

571−58−4 : 1,4−Dimethylnaphthalene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

571−58−4 : 1,4−Dimethylnaphthalene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−30−7 : Phenobarbital sodium 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−30−7 : Phenobarbital sodium 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−41−0 : 5,5−Diphenylhydantoin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−41−0 : 5,5−Diphenylhydantoin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−50−1 : Sucrose 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−50−1 : Sucrose 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−55−6 : 1,2−Propylene glycol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−55−6 : 1,2−Propylene glycol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

576−26−1 : 2,6−Dimethylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

576−26−1 : 2,6−Dimethylphenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−63−6 : 17alpha−Ethinylestradiol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−63−6 : 17alpha−Ethinylestradiol 

 Agonist: 1 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

577−11−7 : Docusate sodium 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

577−11−7 : Docusate sodium 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−74−9 : Chlordane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−74−9 : Chlordane 

 Agonist: 0.033 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57754−85−5 : Clopyralid−olamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57754−85−5 : Clopyralid−olamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−83−0 : Progesterone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−83−0 : Progesterone 

 Agonist: 0.073 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57837−19−1 : Metalaxyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57837−19−1 : Metalaxyl 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−85−2 : Testosterone propionate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−85−2 : Testosterone propionate 

 Agonist: 0.41 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−91−0 : 17alpha−Estradiol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−91−0 : 17alpha−Estradiol 

 Agonist: 1 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

579−66−8 : 2,6−Diethylaniline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

579−66−8 : 2,6−Diethylaniline 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57966−95−7 : Cymoxanil 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57966−95−7 : Cymoxanil 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−97−6 : 7,12−Dimethylbenz(a)anthracene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−97−6 : 7,12−Dimethylbenz(a)anthracene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

58−08−2 : Caffeine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

58−08−2 : Caffeine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

58−14−0 : Pyrimethamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

58−14−0 : Pyrimethamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

58−18−4 : 17−Methyltestosterone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

58−18−4 : 17−Methyltestosterone 

 Agonist: 0.44 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

583−78−8 : 2,5−Dichlorophenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

583−78−8 : 2,5−Dichlorophenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

58394−64−2 : Benzyloctyl adipate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

58394−64−2 : Benzyloctyl adipate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

584−13−4 : 4−Amino−1,2,4−triazole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

584−13−4 : 4−Amino−1,2,4−triazole 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

58430−94−7 : 3,5,5−Trimethylhexyl acetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

58430−94−7 : 3,5,5−Trimethylhexyl acetate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

584−79−2 : Allethrin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

584−79−2 : Allethrin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

584−84−9 : Toluene−2,4−diisocyanate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

584−84−9 : Toluene−2,4−diisocyanate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5850−86−2 : C.I. Acid Orange 8, monosodium salt 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5850−86−2 : C.I. Acid Orange 8, monosodium salt 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

585−34−2 : 3−tert−Butylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

585−34−2 : 3−tert−Butylphenol 

 Agonist: 0.035 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

58−55−9 : Theophylline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

58−55−9 : Theophylline 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

58−56−0 : Pyridoxine hydrochloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

58−56−0 : Pyridoxine hydrochloride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

586−62−9 : Terpinolene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

586−62−9 : Terpinolene 

 Agonist: 0.0059 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5870−93−9 : Heptyl butanoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5870−93−9 : Heptyl butanoate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

58−72−0 : Triphenylethylene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

58−72−0 : Triphenylethylene 

 Agonist: 0.52 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

587−65−5 : 2−Chloro−N−phenylacetamide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

587−65−5 : 2−Chloro−N−phenylacetamide 

 Agonist: 0 Antagonist: 0.005

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

587−85−9 : Diphenylmercury(II) 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

587−85−9 : Diphenylmercury(II) 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

58846−77−8 : Decyl beta−D−glucopyranoside 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

58846−77−8 : Decyl beta−D−glucopyranoside 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

58−85−5 : Biotin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

58−85−5 : Biotin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

58−86−6 : D−Xylose 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

58−86−6 : D−Xylose 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

58−89−9 : Lindane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

58−89−9 : Lindane 

 Agonist: 0.0076 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

58−93−5 : Hydrochlorothiazide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

58−93−5 : Hydrochlorothiazide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

589−68−4 : Tetradecanoic acid, 2,3−dihydroxypropyl ester 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

589−68−4 : Tetradecanoic acid, 2,3−dihydroxypropyl ester 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5902−51−2 : Terbacil 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5902−51−2 : Terbacil 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

59−05−2 : Methotrexate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

59−05−2 : Methotrexate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5915−41−3 : Terbuthylazine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

5915−41−3 : Terbuthylazine 

 Agonist: 0.047 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

59227−89−3 : Laurocapram 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

59227−89−3 : Laurocapram 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

59−30−3 : Folic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

59−30−3 : Folic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

59−40−5 : Sulfaquinoxaline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

59−40−5 : Sulfaquinoxaline 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

594−20−7 : 2,2−Dichloropropane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

594−20−7 : 2,2−Dichloropropane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

59−50−7 : 4−Chloro−3−methylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

59−50−7 : 4−Chloro−3−methylphenol 

 Agonist: 0.044 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

59669−26−0 : Thiodicarb 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

59669−26−0 : Thiodicarb 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

59−67−6 : Nicotinic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

59−67−6 : Nicotinic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

59756−60−4 : Fluridone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

59756−60−4 : Fluridone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

598−55−0 : Methyl carbamate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

598−55−0 : Methyl carbamate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

59−87−0 : Nitrofurazone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

59−87−0 : Nitrofurazone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

599−64−4 : 4−Cumylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

599−64−4 : 4−Cumylphenol 

 Agonist: 0.54 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

599−79−1 : Sulfasalazine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

599−79−1 : Sulfasalazine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

60−09−3 : 4−Aminoazobenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

60−09−3 : 4−Aminoazobenzene 

 Agonist: 0.1 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

60−12−8 : 2−Phenylethanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

60−12−8 : 2−Phenylethanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

60168−88−9 : Fenarimol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

60168−88−9 : Fenarimol 

 Agonist: 0.072 Antagonist: 0.0056

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

602−01−7 : 2,3−Dinitrotoluene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

602−01−7 : 2,3−Dinitrotoluene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

60207−90−1 : Propiconazole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

60207−90−1 : Propiconazole 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

60−33−3 : Linoleic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

60−33−3 : Linoleic acid 

 Agonist: 0 Antagonist: 0.027

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

603−35−0 : Triphenylphosphine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

603−35−0 : Triphenylphosphine 

 Agonist: 0.097 Antagonist: 0.00034

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

60−35−5 : Acetamide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

60−35−5 : Acetamide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

604−75−1 : Oxazepam 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

604−75−1 : Oxazepam 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

60−51−5 : Dimethoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

60−51−5 : Dimethoate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

605−45−8 : Diisopropyl phthalate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

605−45−8 : Diisopropyl phthalate 

 Agonist: 0.024 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

60−54−8 : Tetracycline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

60−54−8 : Tetracycline 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6055−19−2 : Cyclophosphamide monohydrate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6055−19−2 : Cyclophosphamide monohydrate 

 Agonist: 0.079 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

60−56−0 : Methimazole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

60−56−0 : Methimazole 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

60−57−1 : Dieldrin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

60−57−1 : Dieldrin 

 Agonist: 0.022 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

606−20−2 : 2,6−Dinitrotoluene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

606−20−2 : 2,6−Dinitrotoluene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6088−51−3 : 6−Hydroxy−2−naphthyl disulfide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6088−51−3 : 6−Hydroxy−2−naphthyl disulfide 

 Agonist: 0.35 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

609−54−1 : 2,5−Dimethylbenzenesulfonic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

609−54−1 : 2,5−Dimethylbenzenesulfonic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

611−20−1 : Benzonitrile, 2−hydroxy− 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

611−20−1 : Benzonitrile, 2−hydroxy− 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

611−70−1 : Isopropyl phenyl ketone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

611−70−1 : Isopropyl phenyl ketone 

 Agonist: 0.00047 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

612−82−8 : 3,3'−Dimethylbenzidine dihydrochloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

612−82−8 : 3,3'−Dimethylbenzidine dihydrochloride 

 Agonist: 0.12 Antagonist: 6.6e−05

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

614−45−9 : tert−Butyl perbenzoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

614−45−9 : tert−Butyl perbenzoate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6149−03−7 : Sodium 4−octylbenzenesulfonate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6149−03−7 : Sodium 4−octylbenzenesulfonate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6152−33−6 : Sodium 2−phenylphenate tetrahydrate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6152−33−6 : Sodium 2−phenylphenate tetrahydrate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6153−64−6 : Oxytetracycline dihydrate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6153−64−6 : Oxytetracycline dihydrate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

616−45−5 : 2−Pyrrolidinone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

616−45−5 : 2−Pyrrolidinone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

61−73−4 : Methylene blue 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

61−73−4 : Methylene blue 

 Agonist: 0.0016 Antagonist: 0.078

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

61791−12−6 : Cremophor(R) EL 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

61791−12−6 : Cremophor(R) EL 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

61−82−5 : Amitrole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

61−82−5 : Amitrole 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

618−45−1 : 3−Isopropylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

618−45−1 : 3−Isopropylphenol 

 Agonist: 0.015 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6190−65−4 : Deethylatrazine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6190−65−4 : Deethylatrazine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

620−17−7 : 3−Ethylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

620−17−7 : 3−Ethylphenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

621−64−7 : N−Nitrosodipropylamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

621−64−7 : N−Nitrosodipropylamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

62−23−7 : 4−Nitrobenzoic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

62−23−7 : 4−Nitrobenzoic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

622−97−9 : 4−Methylstyrene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

622−97−9 : 4−Methylstyrene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

62−38−4 : Phenylmercuric acetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

62−38−4 : Phenylmercuric acetate 

 Agonist: 0 Antagonist: 0.11

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

625−55−8 : Isopropyl formate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

625−55−8 : Isopropyl formate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

62−56−6 : Thiourea 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

62−56−6 : Thiourea 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6259−76−3 : Hexyl salicylate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6259−76−3 : Hexyl salicylate 

 Agonist: 0.022 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

626−43−7 : 3,5−Dichloroaniline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

626−43−7 : 3,5−Dichloroaniline 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

62−73−7 : Dichlorvos 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

62−73−7 : Dichlorvos 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

62−74−8 : Sodium fluoroacetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

62−74−8 : Sodium fluoroacetate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

62−75−9 : N−Nitrosodimethylamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

62−75−9 : N−Nitrosodimethylamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

627−93−0 : Dimethyl adipate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

627−93−0 : Dimethyl adipate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6285−05−8 : Ethyl 4−chlorophenyl ketone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6285−05−8 : Ethyl 4−chlorophenyl ketone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

628−63−7 : Pentyl acetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

628−63−7 : Pentyl acetate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

62924−70−3 : Flumetralin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

62924−70−3 : Flumetralin 

 Agonist: 0.26 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

629−62−9 : Pentadecane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

629−62−9 : Pentadecane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

629−76−5 : 1−Pentadecanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

629−76−5 : 1−Pentadecanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

630−56−8 : Hydroxyprogesterone caproate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

630−56−8 : Hydroxyprogesterone caproate 

 Agonist: 0.033 Antagonist: 0.045

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

63−05−8 : 4−Androstene−3,17−dione 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

63−05−8 : 4−Androstene−3,17−dione 

 Agonist: 0.12 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6317−18−6 : Methylene bis(thiocyanate) 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6317−18−6 : Methylene bis(thiocyanate) 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

63−25−2 : Carbaryl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

63−25−2 : Carbaryl 

 Agonist: 0.02 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

633−96−5 : C.I. Acid Orange 7 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

633−96−5 : C.I. Acid Orange 7 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

63−42−3 : Lactose 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

63−42−3 : Lactose 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6344−67−8 : 3−Hydroxyfluorene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6344−67−8 : 3−Hydroxyfluorene 

 Agonist: 0.12 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

63449−41−2 : C8−18−Alkydimethylbenzyl ammonium chlorides 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

63449−41−2 : C8−18−Alkydimethylbenzyl ammonium chlorides 

 Agonist: 0.041 Antagonist: 0.038

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6359−82−6 : Acid Yellow 11 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6359−82−6 : Acid Yellow 11 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6359−90−6 : C.I. Acid Yellow 34, monosodium salt 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6359−90−6 : C.I. Acid Yellow 34, monosodium salt 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6359−98−4 : C.I. Acid Yellow 17, disodium salt 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6359−98−4 : C.I. Acid Yellow 17, disodium salt 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

63612−50−0 : Nilutamide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

63612−50−0 : Nilutamide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

636−21−5 : 2−Methylaniline hydrochloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

636−21−5 : 2−Methylaniline hydrochloride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

637−07−0 : Clofibrate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

637−07−0 : Clofibrate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6381−77−7 : Sodium erythorbate (1:1) 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6381−77−7 : Sodium erythorbate (1:1) 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

64−10−8 : Urea, phenyl− 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

64−10−8 : Urea, phenyl− 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6422−86−2 : Bis(2−ethylhexyl) terephthalate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6422−86−2 : Bis(2−ethylhexyl) terephthalate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

64359−81−5 : 4,5−Dichloro−2−octyl−3(2H)−isothiazolone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

64359−81−5 : 4,5−Dichloro−2−octyl−3(2H)−isothiazolone 

 Agonist: 0.002 Antagonist: 0.046

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

643−79−8 : 1,2−Benzenedicarboxaldehyde 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

643−79−8 : 1,2−Benzenedicarboxaldehyde 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

644−97−3 : Phenyl phosphorus dichloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

644−97−3 : Phenyl phosphorus dichloride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

645−56−7 : 4−Propylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

645−56−7 : 4−Propylphenol 

 Agonist: 0.036 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

645−62−5 : 2−Ethyl−2−hexenal 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

645−62−5 : 2−Ethyl−2−hexenal 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6459−94−5 : C.I. Acid Red 114 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6459−94−5 : C.I. Acid Red 114 

 Agonist: 0 Antagonist: 0.033

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

64−67−5 : Diethyl sulfate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

64−67−5 : Diethyl sulfate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

64700−56−7 : Triclopyr−butotyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

64700−56−7 : Triclopyr−butotyl 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

647−42−7 : 3,3,4,4,5,5,6,6,7,7,8,8,8−Tridecafluorooctan−1−ol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

647−42−7 : 3,3,4,4,5,5,6,6,7,7,8,8,8−Tridecafluorooctan−1−ol 

 Agonist: 0.006 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6485−40−1 : R−(−)−Carvone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6485−40−1 : R−(−)−Carvone 

 Agonist: 0.002 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

64−86−8 : Colchicine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

64−86−8 : Colchicine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

648917−13−9 : AVE2865 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

648917−13−9 : AVE2865 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

65−23−6 : Pyridoxine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

65−23−6 : Pyridoxine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

65277−42−1 : Ketoconazole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

65277−42−1 : Ketoconazole 

 Agonist: 0 Antagonist: 0.013

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

654055−01−3 : Morin hydrate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

654055−01−3 : Morin hydrate 

 Agonist: 0.071 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

65−45−2 : Salicylamide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

65−45−2 : Salicylamide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

657−84−1 : Sodium 4−methylbenzenesulfonate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

657−84−1 : Sodium 4−methylbenzenesulfonate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

65−85−0 : Benzoic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

65−85−0 : Benzoic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6610−29−3 : N−Methylhydrazinecarbothioamide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6610−29−3 : N−Methylhydrazinecarbothioamide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

66215−27−8 : Cyromazine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

66215−27−8 : Cyromazine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

66230−04−4 : Esfenvalerate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

66230−04−4 : Esfenvalerate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6624−73−3 : Pentane−1,5−diyl dibenzoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6624−73−3 : Pentane−1,5−diyl dibenzoate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6625−46−3 : C.I. Acid Violet 12, disodium salt 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6625−46−3 : C.I. Acid Violet 12, disodium salt 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

66−27−3 : Methyl methanesulfonate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

66−27−3 : Methyl methanesulfonate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

66332−96−5 : Flutolanil 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

66332−96−5 : Flutolanil 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

66357−35−5 : Ranitidine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

66357−35−5 : Ranitidine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

66441−23−4 : Fenoxaprop−ethyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

66441−23−4 : Fenoxaprop−ethyl 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

66456−53−9 : Adipic acid, polypropyleneglycol, laurate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

66456−53−9 : Adipic acid, polypropyleneglycol, laurate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

66575−29−9 : Forskolin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

66575−29−9 : Forskolin 

 Agonist: 0.029 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

66−71−7 : 1,10−Phenanthroline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

66−71−7 : 1,10−Phenanthroline 

 Agonist: 0 Antagonist: 0.00016

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

66−81−9 : Cycloheximide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

66−81−9 : Cycloheximide 

 Agonist: 0 Antagonist: 0.12

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6683−19−8 : Irganox 1010 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6683−19−8 : Irganox 1010 

 Agonist: 0.11 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

668981−02−0 : CP−863187 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

668981−02−0 : CP−863187 

 Agonist: 0 Antagonist: 0.02

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6706−59−8 : L−Glucitol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6706−59−8 : L−Glucitol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

67−20−9 : Nitrofurantoin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

67−20−9 : Nitrofurantoin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6728−26−3 : (2E)−2−Hexenal 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6728−26−3 : (2E)−2−Hexenal 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

67−30−1 : Tetrac 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

67−30−1 : Tetrac 

 Agonist: 9.4e−05 Antagonist: 0.03

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6734−80−1 : Metam−sodium hydrate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6734−80−1 : Metam−sodium hydrate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

67485−29−4 : Hydramethylnon 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

67485−29−4 : Hydramethylnon 

 Agonist: 0.15 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

67564−91−4 : (2R,6S)−Fenpropimorph 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

67564−91−4 : (2R,6S)−Fenpropimorph 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

676116−04−4 : PD 0343701 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

676116−04−4 : PD 0343701 

 Agonist: 0 Antagonist: 0.05

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

67−68−5 : Dimethyl sulfoxide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

67−68−5 : Dimethyl sulfoxide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

67747−09−5 : Prochloraz 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

67747−09−5 : Prochloraz 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

67786−14−5 : Acid Red 337 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

67786−14−5 : Acid Red 337 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

678−39−7 : 1,1,2,2−Tetrahydroperfluoro−1−decanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

678−39−7 : 1,1,2,2−Tetrahydroperfluoro−1−decanol 

 Agonist: 0.011 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6789−88−4 : Hexyl benzoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6789−88−4 : Hexyl benzoate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68−11−1 : Thioglycolic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68−11−1 : Thioglycolic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68−12−2 : N,N−Dimethylformamide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68−12−2 : N,N−Dimethylformamide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68157−60−8 : Forchlorfenuron 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68157−60−8 : Forchlorfenuron 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68169−03−9 : 2−(Dihydrocyclopentadienyloxy)ethyl methacrylate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68169−03−9 : 2−(Dihydrocyclopentadienyloxy)ethyl methacrylate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

682−01−9 : Tetrapropyl orthosilicate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

682−01−9 : Tetrapropyl orthosilicate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68−22−4 : Norethindrone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68−22−4 : Norethindrone 

 Agonist: 0.67 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68−26−8 : Retinol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68−26−8 : Retinol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

683−18−1 : Dibutyltin dichloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

683−18−1 : Dibutyltin dichloride 

 Agonist: 0 Antagonist: 0.18

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68359−37−5 : Cyfluthrin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68359−37−5 : Cyfluthrin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68392−35−8 : 4−Hydroxytamoxifen 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68392−35−8 : 4−Hydroxytamoxifen 

 Agonist: 0.0032 Antagonist: 0.96

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6846−50−0 : 2,2,4−Trimethyl−1,3−pentanediol diisobutyrate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6846−50−0 : 2,2,4−Trimethyl−1,3−pentanediol diisobutyrate 

 Agonist: 0.024 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

684−93−5 : N−Nitroso−N−methylurea 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

684−93−5 : N−Nitroso−N−methylurea 

 Agonist: 0.0017 Antagonist: 0.0045

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68515−48−0 : DINP branched 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68515−48−0 : DINP branched 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

515−49−1 : 1,2−Benzenedicarboxylic acid, di−C9−11−branched alkyl esters, C10−rich 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68515−49−1 : 1,2−Benzenedicarboxylic acid, di−C9−11−branched alkyl esters, C

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68515−75−3 : Hexanedioic acid, di−C7−9−branched and linear alkyl esters 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68515−75−3 : Hexanedioic acid, di−C7−9−branched and linear alkyl ester

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68555−86−2 : Acid Orange 156 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68555−86−2 : Acid Orange 156 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68609−97−2 : C12−14−Alkyl glycidyl ether 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68609−97−2 : C12−14−Alkyl glycidyl ether 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68694−11−1 : Triflumizole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68694−11−1 : Triflumizole 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68917−18−0 : Cornmint oil 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68917−18−0 : Cornmint oil 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6893−02−3 : 3,5,3'−Triiodothyronine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6893−02−3 : 3,5,3'−Triiodothyronine 

 Agonist: 0.12 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68959−20−6 : Disiquonium chloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68959−20−6 : Disiquonium chloride 

 Agonist: 0.018 Antagonist: 0.0014

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68−96−2 : 17alpha−Hydroxyprogesterone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68−96−2 : 17alpha−Hydroxyprogesterone 

 Agonist: 0.22 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

69−09−0 : Chlorpromazine hydrochloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

69−09−0 : Chlorpromazine hydrochloride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6915−15−7 : Malic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6915−15−7 : Malic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6923−22−4 : Monocrotophos 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

6923−22−4 : Monocrotophos 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

692−86−4 : Ethyl undec−10−enoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

692−86−4 : Ethyl undec−10−enoate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

69327−76−0 : Buprofezin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

69327−76−0 : Buprofezin 

 Agonist: 0 Antagonist: 0.014

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

69377−81−7 : Fluroxypyr 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

69377−81−7 : Fluroxypyr 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

695−06−7 : gamma−Caprolactone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

695−06−7 : gamma−Caprolactone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

69655−05−6 : 2',3'−Dideoxyinosine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

69655−05−6 : 2',3'−Dideoxyinosine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

69−65−8 : D−Mannitol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

69−65−8 : D−Mannitol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

69−72−7 : Salicylic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

69−72−7 : Salicylic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

69−74−9 : Cytarabine hydrochloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

69−74−9 : Cytarabine hydrochloride 

 Agonist: 0.025 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

69806−40−2 : Haloxyfop−methyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

69806−40−2 : Haloxyfop−methyl 

 Agonist: 0 Antagonist: 0.023

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

69806−50−4 : Fluazifop−butyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

69806−50−4 : Fluazifop−butyl 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7011−83−8 : 2(3H)−Furanone, 5−hexyldihydro−5−methyl− 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7011−83−8 : 2(3H)−Furanone, 5−hexyldihydro−5−methyl− 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

70−55−3 : 4−Toluenesulfonamide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

70−55−3 : 4−Toluenesulfonamide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

705−60−2 : (2−Nitro−1−propenyl)benzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

705−60−2 : (2−Nitro−1−propenyl)benzene 

 Agonist: 0 Antagonist: 0.019

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

70568−60−4 : 4−Butylcyclohexanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

70568−60−4 : 4−Butylcyclohexanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

706−14−9 : gamma−Decanolactone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

706−14−9 : gamma−Decanolactone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7080−50−4 : Chloramine−T trihydrate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7080−50−4 : Chloramine−T trihydrate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

709−98−8 : Propanil 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

709−98−8 : Propanil 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

71−23−8 : 1−Propanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

71−23−8 : 1−Propanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

712−50−5 : Cyclohexylphenylketone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

712−50−5 : Cyclohexylphenylketone 

 Agonist: 0.038 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

71283−80−2 : Fenoxaprop−P−ethyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

71283−80−2 : Fenoxaprop−P−ethyl 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

71526−07−3 : MON−4660 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

71526−07−3 : MON−4660 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7173−51−5 : Didecyldimethylammonium chloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7173−51−5 : Didecyldimethylammonium chloride 

 Agonist: 0.0032 Antagonist: 0.09

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

71751−41−2 : Abamectin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

71751−41−2 : Abamectin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

717−74−8 : 1,3,5−Triisopropylbenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

717−74−8 : 1,3,5−Triisopropylbenzene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7212−44−4 : Nerolidol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7212−44−4 : Nerolidol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

72178−02−0 : Fomesafen 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

72178−02−0 : Fomesafen 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

72−20−8 : Endrin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

72−20−8 : Endrin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

72−33−3 : Mestranol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

72−33−3 : Mestranol 

 Agonist: 0.91 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

72−43−5 : Methoxychlor 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

72−43−5 : Methoxychlor 

 Agonist: 0.38 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

72490−01−8 : Fenoxycarb 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

72490−01−8 : Fenoxycarb 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

725228−45−5 : AVE5638 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

725228−45−5 : AVE5638 

 Agonist: 0.0091 Antagonist: 0.0071

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

72−54−8 : p,p'−DDD 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

72−54−8 : p,p'−DDD 

 Agonist: 0.075 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

72−55−9 : p,p'−DDE 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

72−55−9 : p,p'−DDE 

 Agonist: 0.11 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7287−19−6 : Prometryn 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7287−19−6 : Prometryn 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

732−11−6 : Phosmet 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

732−11−6 : Phosmet 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

73−22−3 : l−Tryptophan 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

73−22−3 : l−Tryptophan 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

732−26−3 : 2,4,6−Tris(tert−butyl)phenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

732−26−3 : 2,4,6−Tris(tert−butyl)phenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

73−31−4 : Melatonin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

73−31−4 : Melatonin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7378−99−6 : N,N−Dimethyloctylamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7378−99−6 : N,N−Dimethyloctylamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7398−69−8 : Dimethyldiallylammonium chloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7398−69−8 : Dimethyldiallylammonium chloride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

74051−80−2 : Sethoxydim 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

74051−80−2 : Sethoxydim 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

74115−24−5 : Clofentezine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

74115−24−5 : Clofentezine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

741−58−2 : Bensulide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

741−58−2 : Bensulide 

 Agonist: 0 Antagonist: 0.0087

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

742693−38−5 : SSR504734 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

742693−38−5 : SSR504734 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

744−45−6 : Diphenyl isophthalate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

744−45−6 : Diphenyl isophthalate 

 Agonist: 0.029 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7487−94−7 : Mercuric chloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7487−94−7 : Mercuric chloride 

 Agonist: 0 Antagonist: 0.0051

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

75330−75−5 : Lovastatin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

75330−75−5 : Lovastatin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

753−73−1 : Dimethyltin dichloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

753−73−1 : Dimethyltin dichloride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7540−51−4 : (S)−(−)−beta−Citronellol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7540−51−4 : (S)−(−)−beta−Citronellol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

754−91−6 : PFOSA 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

754−91−6 : PFOSA 

 Agonist: 0.056 Antagonist: 0.033

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

75−50−3 : Trimethylamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

75−50−3 : Trimethylamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

75−60−5 : Dimethylarsinic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

75−60−5 : Dimethylarsinic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

75−64−9 : tert−Butylamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

75−64−9 : tert−Butylamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

756−79−6 : Dimethyl methylphosphonate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

756−79−6 : Dimethyl methylphosphonate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

75−86−5 : 2−Hydroxy−2−methylpropanenitrile 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

75−86−5 : 2−Hydroxy−2−methylpropanenitrile 

 Agonist: 0.0035 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

75−99−0 : Dalapon 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

75−99−0 : Dalapon 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

759−94−4 : EPTC 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

759−94−4 : EPTC 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

760−23−6 : 3,4−Dichloro−1−butene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

760−23−6 : 3,4−Dichloro−1−butene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

76−03−9 : Trichloroacetic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

76−03−9 : Trichloroacetic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

762−04−9 : Diethyl phosphite 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

762−04−9 : Diethyl phosphite 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7632−00−0 : Sodium nitrite 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7632−00−0 : Sodium nitrite 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

76−44−8 : Heptachlor 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

76−44−8 : Heptachlor 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

76−49−3 : Bornyl acetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

76−49−3 : Bornyl acetate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

76578−14−8 : Quizalofop−ethyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

76578−14−8 : Quizalofop−ethyl 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7659−86−1 : 2−Ethylhexyl sulfanylacetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7659−86−1 : 2−Ethylhexyl sulfanylacetate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7664−38−2 : Phosphoric acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7664−38−2 : Phosphoric acid 

 Agonist: 0.0074 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

76738−62−0 : Paclobutrazol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

76738−62−0 : Paclobutrazol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7681−76−7 : Ronidazole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7681−76−7 : Ronidazole 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7681−82−5 : Sodium iodide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7681−82−5 : Sodium iodide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

76−87−9 : Triphenyltin hydroxide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

76−87−9 : Triphenyltin hydroxide 

 Agonist: 0 Antagonist: 0.00041

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7696−12−0 : Tetramethrin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7696−12−0 : Tetramethrin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

769−92−6 : 4−tert−Butylaniline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

769−92−6 : 4−tert−Butylaniline 

 Agonist: 0.0037 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

770−35−4 : 1−Phenoxy−2−propanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

770−35−4 : 1−Phenoxy−2−propanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

77−06−5 : Gibberellic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

77−06−5 : Gibberellic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

77−09−8 : Phenolphthalein 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

77−09−8 : Phenolphthalein 

 Agonist: 0.36 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

77−40−7 : Bisphenol B 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

77−40−7 : Bisphenol B 

 Agonist: 0.75 Antagonist: 0.0031

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7747−35−5 : 5−Ethyl−1−aza−3,7−dioxabicyclo[3.3.0]octane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7747−35−5 : 5−Ethyl−1−aza−3,7−dioxabicyclo[3.3.0]octane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

77−47−4 : Hexachlorocyclopentadiene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

77−47−4 : Hexachlorocyclopentadiene 

 Agonist: 0.022 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

77−48−5 : 1,3−Dibromo−5,5−dimethylhydantoin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

77−48−5 : 1,3−Dibromo−5,5−dimethylhydantoin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

77501−63−4 : Lactofen 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

77501−63−4 : Lactofen 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7757−79−1 : Potassium nitrate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7757−79−1 : Potassium nitrate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

77−71−4 : 5,5−Dimethylhydantoin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

77−71−4 : 5,5−Dimethylhydantoin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7773−06−0 : Ammonium sulfamate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7773−06−0 : Ammonium sulfamate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

77−73−6 : Dicyclopentadiene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

77−73−6 : Dicyclopentadiene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7775−27−1 : Sodium persulfate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7775−27−1 : Sodium persulfate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

77−78−1 : Dimethyl sulfate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

77−78−1 : Dimethyl sulfate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7779−27−3 : 1,3,5−Triethylhexahydro−s−triazine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7779−27−3 : 1,3,5−Triethylhexahydro−s−triazine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

77−83−8 : Ethyl methylphenylglycidate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

77−83−8 : Ethyl methylphenylglycidate 

 Agonist: 0.0064 Antagonist: 0.016

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7785−26−4 : (−)−alpha−Pinene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7785−26−4 : (−)−alpha−Pinene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

77−86−1 : Tromethamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

77−86−1 : Tromethamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7786−34−7 : Mevinphos 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

7786−34−7 : Mevinphos 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

77−90−7 : Acetyl tributyl citrate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

77−90−7 : Acetyl tributyl citrate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

77−92−9 : Citric acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

77−92−9 : Citric acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

77−93−0 : Triethyl citrate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

77−93−0 : Triethyl citrate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

78−07−9 : Ethyltriethoxysilane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

78−07−9 : Ethyltriethoxysilane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

78−11−5 : Pentaerythritol tetranitrate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

78−11−5 : Pentaerythritol tetranitrate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

78−40−0 : Triethyl phosphate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

78−40−0 : Triethyl phosphate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

78−42−2 : Tris(2−ethylhexyl) phosphate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

78−42−2 : Tris(2−ethylhexyl) phosphate 

 Agonist: 0.0046 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

78473−71−9 : Enterolactone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

78473−71−9 : Enterolactone 

 Agonist: 0.1 Antagonist: 8.8e−05

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

78−48−8 : Tribufos 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

78−48−8 : Tribufos 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

78491−02−8 : Diazolidinyl urea 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

78491−02−8 : Diazolidinyl urea 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

78−51−3 : Tris(2−butoxyethyl) phosphate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

78−51−3 : Tris(2−butoxyethyl) phosphate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

78587−05−0 : Hexythiazox 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

78587−05−0 : Hexythiazox 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

78−59−1 : Isophorone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

78−59−1 : Isophorone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

78−63−7 : 2,5−Dimethyl−2,5−di−(tert−butylperoxy)hexane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

78−63−7 : 2,5−Dimethyl−2,5−di−(tert−butylperoxy)hexane 

 Agonist: 0.013 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

78−69−3 : 3,7−Dimethyl−3−octanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

78−69−3 : 3,7−Dimethyl−3−octanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

78−70−6 : Linalool 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

78−70−6 : Linalool 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

78−82−0 : 2−Methylpropanenitrile 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

78−82−0 : 2−Methylpropanenitrile 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

789−02−6 : o,p'−DDT 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

789−02−6 : o,p'−DDT 

 Agonist: 0.49 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

78−96−6 : 1−Amino−2−propanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

78−96−6 : 1−Amino−2−propanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79−06−1 : Acrylamide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79−06−1 : Acrylamide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79098−20−7 : 4−Chloropentylbenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79098−20−7 : 4−Chloropentylbenzene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79−14−1 : Glycolic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79−14−1 : Glycolic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79−16−3 : N−Methylacetamide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79−16−3 : N−Methylacetamide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79241−46−6 : Fluazifop−P−butyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79241−46−6 : Fluazifop−P−butyl 

 Agonist: 0.023 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79−24−3 : Nitroethane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79−24−3 : Nitroethane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79277−27−3 : Thifensulfuron−methyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79277−27−3 : Thifensulfuron−methyl 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79−39−0 : Methacrylamide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79−39−0 : Methacrylamide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79−43−6 : Dichloroacetic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79−43−6 : Dichloroacetic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79−44−7 : Dimethylcarbamoyl chloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79−44−7 : Dimethylcarbamoyl chloride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79538−32−2 : Tefluthrin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79538−32−2 : Tefluthrin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79−57−2 : Oxytetracycline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79−57−2 : Oxytetracycline 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79622−59−6 : Fluazinam 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79622−59−6 : Fluazinam 

 Agonist: 0 Antagonist: 0.0077

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

797−63−7 : Norgestrel 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

797−63−7 : Norgestrel 

 Agonist: 0.43 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79902−63−9 : Simvastatin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79902−63−9 : Simvastatin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79−92−5 : 2,2−Dimethyl−3−methylenebicyclo[2.2.1]heptane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79−92−5 : 2,2−Dimethyl−3−methylenebicyclo[2.2.1]heptane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79−94−7 : 3,3',5,5'−Tetrabromobisphenol A 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79−94−7 : 3,3',5,5'−Tetrabromobisphenol A 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79−95−8 : 2,2',6,6'−Tetrachlorobisphenol A 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79−95−8 : 2,2',6,6'−Tetrachlorobisphenol A 

 Agonist: 0.24 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79983−71−4 : Hexaconazole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

79983−71−4 : Hexaconazole 

 Agonist: 0.00014 Antagonist: 0.0061

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

8000−34−8 : Clove leaf oil 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

8000−34−8 : Clove leaf oil 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

8000−41−7 : Terpineol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

8000−41−7 : Terpineol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

8001−54−5 : Benzalkonium chloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

8001−54−5 : Benzalkonium chloride 

 Agonist: 0 Antagonist: 0.06

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

8004−92−0 : C.I. Acid Yellow 3 disodium salt 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

8004−92−0 : C.I. Acid Yellow 3 disodium salt 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

80−05−7 : Bisphenol A 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

80−05−7 : Bisphenol A 

 Agonist: 0.65 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

8006−90−4 : Peppermint oil 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

8006−90−4 : Peppermint oil 

 Agonist: 0.0073 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

8007−70−3 : Anise oil 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

8007−70−3 : Anise oil 

 Agonist: 0.055 Antagonist: 0.0034

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

80−07−9 : 4,4'−Dichlorodiphenyl sulfone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

80−07−9 : 4,4'−Dichlorodiphenyl sulfone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

80−08−0 : Dapsone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

80−08−0 : Dapsone 

 Agonist: 0.0016 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

80−09−1 : 4,4'−Sulfonyldiphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

80−09−1 : 4,4'−Sulfonyldiphenol 

 Agonist: 0.32 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

80−15−9 : Cumene hydroperoxide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

80−15−9 : Cumene hydroperoxide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

8018−01−7 : Mancozeb 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

8018−01−7 : Mancozeb 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

80−26−2 : alpha−Terpinyl acetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

80−26−2 : alpha−Terpinyl acetate 

 Agonist: 0.0086 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

80−27−3 : Terpinyl propionate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

80−27−3 : Terpinyl propionate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

80−43−3 : Dicumyl peroxide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

80−43−3 : Dicumyl peroxide 

 Agonist: 0.29 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

80−46−6 : 4−(2−Methylbutan−2−yl)phenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

80−46−6 : 4−(2−Methylbutan−2−yl)phenol 

 Agonist: 0.4 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

80−54−6 : 3−(4−tert−Butylphenyl)−2−methylpropanal 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

80−54−6 : 3−(4−tert−Butylphenyl)−2−methylpropanal 

 Agonist: 0.0056 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

80−56−8 : alpha−Pinene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

80−56−8 : alpha−Pinene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

80844−07−1 : Etofenprox 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

80844−07−1 : Etofenprox 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

81−07−2 : Saccharin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

81−07−2 : Saccharin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

81131−70−6 : Pravastatin sodium 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

81131−70−6 : Pravastatin sodium 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

81334−34−1 : Imazapyr 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

81334−34−1 : Imazapyr 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

81335−37−7 : Imazaquin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

81335−37−7 : Imazaquin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

81335−77−5 : Imazethapyr 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

81335−77−5 : Imazethapyr 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

81405−85−8 : Imazmethabenz 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

81405−85−8 : Imazmethabenz 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

81406−37−3 : Fluroxypyr−meptyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

81406−37−3 : Fluroxypyr−meptyl 

 Agonist: 0.012 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

81741−28−8 : Tributyltetradecylphosphonium chloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

81741−28−8 : Tributyltetradecylphosphonium chloride 

 Agonist: 0.04 Antagonist: 0.061

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

81777−89−1 : Clomazone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

81777−89−1 : Clomazone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

81−81−2 : Warfarin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

81−81−2 : Warfarin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

818−61−1 : 2−Hydroxyethyl acrylate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

818−61−1 : 2−Hydroxyethyl acrylate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

81−88−9 : Rhodamine B 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

81−88−9 : Rhodamine B 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

81−90−3 : Phenolphthalin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

81−90−3 : Phenolphthalin 

 Agonist: 0.043 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

822−06−0 : 1,6−Diisocyanatohexane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

822−06−0 : 1,6−Diisocyanatohexane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

82385−42−0 : Sodium saccharin hydrate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

82385−42−0 : Sodium saccharin hydrate 

 Agonist: 0.021 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

824−39−5 : Sodium 2−nitrophenolate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

824−39−5 : Sodium 2−nitrophenolate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

82469−79−2 : Butyryl trihexyl citrate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

82469−79−2 : Butyryl trihexyl citrate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

824−78−2 : Sodium 4−nitrophenolate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

824−78−2 : Sodium 4−nitrophenolate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

82558−50−7 : Isoxaben 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

82558−50−7 : Isoxaben 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

82640−04−8 : Raloxifene hydrochloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

82640−04−8 : Raloxifene hydrochloride 

 Agonist: 0 Antagonist: 0.97

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

82657−04−3 : Bifenthrin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

82657−04−3 : Bifenthrin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

826−62−0 : 3a,4,7,7a−Tetrahydro−4,7−methanoisobenzofuran−1,3−dione 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

826−62−0 : 3a,4,7,7a−Tetrahydro−4,7−methanoisobenzofuran−1,3−dione 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

82−68−8 : Pentachloronitrobenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

82−68−8 : Pentachloronitrobenzene 

 Agonist: 0.0036 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

827−19−0 : Sodium 2,5−dimethylbenzenesulfonate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

827−19−0 : Sodium 2,5−dimethylbenzenesulfonate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

827−21−4 : Benzenesulfonic acid, 2,4−dimethyl−, sodium salt 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

827−21−4 : Benzenesulfonic acid, 2,4−dimethyl−, sodium salt 

 Agonist: 0.021 Antagonist: 0.052

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

828−00−2 : Dimethoxane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

828−00−2 : Dimethoxane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

83−32−9 : Acenaphthene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

83−32−9 : Acenaphthene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

83−41−0 : 1,2−Dimethyl−3−nitrobenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

83−41−0 : 1,2−Dimethyl−3−nitrobenzene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

834−12−8 : Ametryn 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

834−12−8 : Ametryn 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

83657−24−3 : Diniconazole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

83657−24−3 : Diniconazole 

 Agonist: 0 Antagonist: 0.0071

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

83−67−0 : Theobromine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

83−67−0 : Theobromine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

83−79−4 : Rotenone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

83−79−4 : Rotenone 

 Agonist: 9.8e−05 Antagonist: 0.00011

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

83834−59−7 : 2−Ethylhexyl trans−4−methoxycinnamate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

83834−59−7 : 2−Ethylhexyl trans−4−methoxycinnamate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

83−88−5 : Riboflavin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

83−88−5 : Riboflavin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

838−85−7 : Diphenyl phosphate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

838−85−7 : Diphenyl phosphate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

838−88−0 : 4,4'−Methylenebis(2−methylaniline) 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

838−88−0 : 4,4'−Methylenebis(2−methylaniline) 

 Agonist: 0.066 Antagonist: 0.01

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

84087−01−4 : Quinclorac 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

84087−01−4 : Quinclorac 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

84−16−2 : meso−Hexestrol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

84−16−2 : meso−Hexestrol 

 Agonist: 1 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

842−07−9 : C.I. Solvent Yellow 14 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

842−07−9 : C.I. Solvent Yellow 14 

 Agonist: 0.065 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

84371−65−3 : Mifepristone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

84371−65−3 : Mifepristone 

 Agonist: 0.0073 Antagonist: 0.46

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

84−61−7 : Dicyclohexyl phthalate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

84−61−7 : Dicyclohexyl phthalate 

 Agonist: 0.029 Antagonist: 0.024

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

84−66−2 : Diethyl phthalate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

84−66−2 : Diethyl phthalate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

84−69−5 : Diisobutyl phthalate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

84−69−5 : Diisobutyl phthalate 

 Agonist: 0.05 Antagonist: 0.068

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

84−74−2 : Dibutyl phthalate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

84−74−2 : Dibutyl phthalate 

 Agonist: 0.041 Antagonist: 0.069

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

84−75−3 : Dihexyl phthalate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

84−75−3 : Dihexyl phthalate 

 Agonist: 0.021 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

84852−15−3 : 4−Nonylphenol, branched 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

84852−15−3 : 4−Nonylphenol, branched 

 Agonist: 0.6 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

85−01−8 : Phenanthrene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

85−01−8 : Phenanthrene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

851916−42−2 : MK−812 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

851916−42−2 : MK−812 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

85264−33−1 : (3,5−Dimethyl−1H−pyrazol−1−yl)methanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

85264−33−1 : (3,5−Dimethyl−1H−pyrazol−1−yl)methanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

85−40−5 : 1,2,3,6−Tetrahydrophthalimide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

85−40−5 : 1,2,3,6−Tetrahydrophthalimide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

85−41−6 : Phthalimide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

85−41−6 : Phthalimide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

85507−79−5 : Phthalic acid, diundecyl ester, branched and linear 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

85507−79−5 : Phthalic acid, diundecyl ester, branched and linear 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

85509−19−9 : Flusilazole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

85509−19−9 : Flusilazole 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

85532−75−8 : PK 11195 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

85532−75−8 : PK 11195 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

85−68−7 : Butyl benzyl phthalate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

85−68−7 : Butyl benzyl phthalate 

 Agonist: 0.25 Antagonist: 0.001

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

860−22−0 : C.I. Acid Blue 74 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

860−22−0 : C.I. Acid Blue 74 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

862243−29−6 : AVE9423 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

862243−29−6 : AVE9423 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

86−30−6 : N−Nitrosodiphenylamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

86−30−6 : N−Nitrosodiphenylamine 

 Agonist: 0.026 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

86386−73−4 : Fluconazole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

86386−73−4 : Fluconazole 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

864283−48−7 : GSK232420A 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

864283−48−7 : GSK232420A 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

86479−06−3 : Hexaflumuron 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

86479−06−3 : Hexaflumuron 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

86−50−0 : Azinphos−methyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

86−50−0 : Azinphos−methyl 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

86−73−7 : Fluorene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

86−73−7 : Fluorene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

86−87−3 : 1−Naphthaleneacetic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

86−87−3 : 1−Naphthaleneacetic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

868−85−9 : Dimethyl hydrogen phosphite 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

868−85−9 : Dimethyl hydrogen phosphite 

 Agonist: 0.026 Antagonist: 0.066

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

87−01−4 : 7−(Dimethylamino)−4−methylcoumarin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

87−01−4 : 7−(Dimethylamino)−4−methylcoumarin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

87−18−3 : 4−tert−Butylphenyl salicylate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

87−18−3 : 4−tert−Butylphenyl salicylate 

 Agonist: 0.076 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

87−24−1 : Ethyl 2−methylbenzoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

87−24−1 : Ethyl 2−methylbenzoate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

872−50−4 : N−Methyl−2−pyrrolidone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

872−50−4 : N−Methyl−2−pyrrolidone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

87−25−2 : Ethyl anthranilate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

87−25−2 : Ethyl anthranilate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

87392−12−9 : S−Metolachlor 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

87392−12−9 : S−Metolachlor 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

87546−18−7 : Flumiclorac−pentyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

87546−18−7 : Flumiclorac−pentyl 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

87−61−6 : 1,2,3−Trichlorobenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

87−61−6 : 1,2,3−Trichlorobenzene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

87−62−7 : 2,6−Dimethylaniline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

87−62−7 : 2,6−Dimethylaniline 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

87674−68−8 : Dimethenamid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

87674−68−8 : Dimethenamid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

87−68−3 : Hexachloro−1,3−butadiene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

87−68−3 : Hexachloro−1,3−butadiene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

87−69−4 : L−Tartaric acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

87−69−4 : L−Tartaric acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

877−24−7 : Monopotassium phthalate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

877−24−7 : Monopotassium phthalate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

87818−31−3 : Cinmethylin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

87818−31−3 : Cinmethylin 

 Agonist: 0.028 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

87820−88−0 : Tralkoxydim 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

87820−88−0 : Tralkoxydim 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

87−86−5 : Pentachlorophenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

87−86−5 : Pentachlorophenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

87−90−1 : Symclosene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

87−90−1 : Symclosene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

88−04−0 : 4−Chloro−3,5−dimethylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

88−04−0 : 4−Chloro−3,5−dimethylphenol 

 Agonist: 0.063 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

88−06−2 : 2,4,6−Trichlorophenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

88−06−2 : 2,4,6−Trichlorophenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

88−12−0 : N−Vinyl−2−pyrrolidone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

88−12−0 : N−Vinyl−2−pyrrolidone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

88−18−6 : 2−tert−Butylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

88−18−6 : 2−tert−Butylphenol 

 Agonist: 0.009 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

88−24−4 : 2,2'−Methylenebis(ethyl−6−tert−butylphenol) 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

88−24−4 : 2,2'−Methylenebis(ethyl−6−tert−butylphenol) 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

88−30−2 : 3−Trifluoromethyl−4−nitrophenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

88−30−2 : 3−Trifluoromethyl−4−nitrophenol 

 Agonist: 0.0095 Antagonist: 0.038

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

88−41−5 : 2−tert−Butylcyclohexyl acetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

88−41−5 : 2−tert−Butylcyclohexyl acetate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

88−58−4 : 2,5−Di−tert−butylbenzene−1,4−diol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

88−58−4 : 2,5−Di−tert−butylbenzene−1,4−diol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

88−60−8 : 2−tert−Butyl−5−methylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

88−60−8 : 2−tert−Butyl−5−methylphenol 

 Agonist: 0.057 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

88671−89−0 : Myclobutanil 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

88671−89−0 : Myclobutanil 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

88−69−7 : 2−Isopropylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

88−69−7 : 2−Isopropylphenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

88−72−2 : 2−Nitrotoluene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

88−72−2 : 2−Nitrotoluene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

88−74−4 : 2−Nitroaniline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

88−74−4 : 2−Nitroaniline 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

88−75−5 : 2−Nitrophenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

88−75−5 : 2−Nitrophenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

88−85−7 : Dinoseb 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

88−85−7 : Dinoseb 

 Agonist: 0 Antagonist: 0.00021

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

89−04−3 : Trioctyl trimellitate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

89−04−3 : Trioctyl trimellitate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

89−71−4 : Methyl 2−methylbenzoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

89−71−4 : Methyl 2−methylbenzoate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

89−72−5 : 2−(Butan−2−yl)phenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

89−72−5 : 2−(Butan−2−yl)phenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

89−78−1 : dl−Menthol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

89−78−1 : dl−Menthol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

89−83−8 : Thymol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

89−83−8 : Thymol 

 Agonist: 0.0072 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

89−87−2 : 1,3−Dimethyl−4−nitrobenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

89−87−2 : 1,3−Dimethyl−4−nitrobenzene 

 Agonist: 0.0098 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

90−00−6 : 2−Ethylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

90−00−6 : 2−Ethylphenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

90−02−8 : Salicylaldehyde 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

90−02−8 : Salicylaldehyde 

 Agonist: 0.035 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

9003−11−6 : Pluronic F−127 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

9003−11−6 : Pluronic F−127 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

90−04−0 : 2−Anisidine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

90−04−0 : 2−Anisidine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

9004−82−4 : Sodium lauryl polyoxyethylene ether sulfate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

9004−82−4 : Sodium lauryl polyoxyethylene ether sulfate 

 Agonist: 0.0051 Antagonist: 0.11

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

9004−96−0 : Polyoxyethylene monoleate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

9004−96−0 : Polyoxyethylene monoleate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

90−05−1 : 2−Methoxyphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

90−05−1 : 2−Methoxyphenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

9005−65−6 : Polysorbate 80 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

9005−65−6 : Polysorbate 80 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

90−12−0 : 1−Methylnaphthalene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

90−12−0 : 1−Methylnaphthalene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

90−15−3 : 1−Naphthol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

90−15−3 : 1−Naphthol 

 Agonist: 0.033 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

9016−00−6 : Polydimethylsiloxane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

9016−00−6 : Polydimethylsiloxane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

9016−87−9 : Isocyanic acid, polymethylenepolyphenylene ester 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

9016−87−9 : Isocyanic acid, polymethylenepolyphenylene ester 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

90−30−2 : N−Phenyl−1−naphthylamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

90−30−2 : N−Phenyl−1−naphthylamine 

 Agonist: 0.031 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

90357−06−5 : Bicalutamide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

90357−06−5 : Bicalutamide 

 Agonist: 0.0069 Antagonist: 0.13

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

90−43−7 : 2−Phenylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

90−43−7 : 2−Phenylphenol 

 Agonist: 0.015 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

90−72−2 : 2,4,6−Tris(dimethylaminomethyl)phenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

90−72−2 : 2,4,6−Tris(dimethylaminomethyl)phenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

90823−38−4 : Denatonium saccharide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

90823−38−4 : Denatonium saccharide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

90−94−8 : Michler's ketone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

90−94−8 : Michler's ketone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

91082−17−6 : C10−21 sulfonic acids phenyl esters 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

91082−17−6 : C10−21 sulfonic acids phenyl esters 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

91−20−3 : Naphthalene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

91−20−3 : Naphthalene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

91−22−5 : Quinoline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

91−22−5 : Quinoline 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

91465−08−6 : lambda−Cyhalothrin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

91465−08−6 : lambda−Cyhalothrin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

91−53−2 : Ethoxyquin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

91−53−2 : Ethoxyquin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

91−59−8 : 2−Naphthylamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

91−59−8 : 2−Naphthylamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

91−62−3 : 6−Methylquinoline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

91−62−3 : 6−Methylquinoline 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

91−64−5 : Coumarin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

91−64−5 : Coumarin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

91−66−7 : N,N−Diethylaniline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

91−66−7 : N,N−Diethylaniline 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

919−30−2 : 3−Aminopropyltriethoxysilane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

919−30−2 : 3−Aminopropyltriethoxysilane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

92−04−6 : 2−Chloro−4−phenylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

92−04−6 : 2−Chloro−4−phenylphenol 

 Agonist: 0.16 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

924−16−3 : N−Nitrosodibutylamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

924−16−3 : N−Nitrosodibutylamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

92−52−4 : Biphenyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

92−52−4 : Biphenyl 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

92−68−2 : 4−Cyclohexylcyclohexanone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

92−68−2 : 4−Cyclohexylcyclohexanone 

 Agonist: 0.036 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

92−69−3 : 4−Phenylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

92−69−3 : 4−Phenylphenol 

 Agonist: 0.32 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

92−84−2 : Phenothiazine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

92−84−2 : Phenothiazine 

 Agonist: 0.01 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

92−87−5 : Benzidine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

92−87−5 : Benzidine 

 Agonist: 0.013 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

928−96−1 : (Z)−3−Hexen−1−ol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

928−96−1 : (Z)−3−Hexen−1−ol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

929601−09−2 : SR58611 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

929601−09−2 : SR58611 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

930−55−2 : N−Nitrosopyrrolidine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

930−55−2 : N−Nitrosopyrrolidine 

 Agonist: 0.0024 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

93−08−3 : 2'−Acetonaphthone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

93−08−3 : 2'−Acetonaphthone 

 Agonist: 0.0049 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

93−15−2 : Methyleugenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

93−15−2 : Methyleugenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

93−56−1 : Styrene glycol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

93−56−1 : Styrene glycol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

93−65−2 : Mecoprop 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

93−65−2 : Mecoprop 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

93−76−5 : 2,4,5−Trichlorophenoxyacetic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

93−76−5 : 2,4,5−Trichlorophenoxyacetic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

938−16−9 : tert−Butyl phenyl ketone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

938−16−9 : tert−Butyl phenyl ketone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

93−89−0 : Ethyl benzoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

93−89−0 : Ethyl benzoate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

93−92−5 : Benzenemethanol, alpha−methyl−, acetate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

93−92−5 : Benzenemethanol, alpha−methyl−, acetate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

93−99−2 : Phenyl benzoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

93−99−2 : Phenyl benzoate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−08−6 : Ethyl 4−methylbenzoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−08−6 : Ethyl 4−methylbenzoate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−09−7 : Benzocaine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−09−7 : Benzocaine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−13−3 : Propylparaben 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−13−3 : Propylparaben 

 Agonist: 0.3 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

941−69−5 : 1−Phenyl−1H−pyrrole−2,5−dione 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

941−69−5 : 1−Phenyl−1H−pyrrole−2,5−dione 

 Agonist: 0 Antagonist: 0.02

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−18−8 : Benzylparaben 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−18−8 : Benzylparaben 

 Agonist: 0.35 Antagonist: 0.011

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−26−8 : Butylparaben 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−26−8 : Butylparaben 

 Agonist: 0.38 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−28−0 : Triethylene glycol bis(2−ethylhexanoate) 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−28−0 : Triethylene glycol bis(2−ethylhexanoate) 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94361−06−5 : Cyproconazole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94361−06−5 : Cyproconazole 

 Agonist: 0.042 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−46−2 : Isopentyl benzoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−46−2 : Isopentyl benzoate 

 Agonist: 0.0038 Antagonist: 0.0087

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−47−3 : 2−Phenylethyl benzoate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−47−3 : 2−Phenylethyl benzoate 

 Agonist: 0.011 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−59−7 : Safrole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−59−7 : Safrole 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−60−0 : Dimethyl hexahydroterephthalate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−60−0 : Dimethyl hexahydroterephthalate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−71−3 : 2−Ethoxyphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−71−3 : 2−Ethoxyphenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−74−6 : MCPA 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−74−6 : MCPA 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−75−7 : 2,4−Dichlorophenoxyacetic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−75−7 : 2,4−Dichlorophenoxyacetic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−80−4 : 2,4−D 1−butyl ester 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−80−4 : 2,4−D 1−butyl ester 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−81−5 : MCPB 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−81−5 : MCPB 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−82−6 : 2,4−DB 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−82−6 : 2,4−DB 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−91−7 : N,N'−Disalicylidene−1,2−diaminopropane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−91−7 : N,N'−Disalicylidene−1,2−diaminopropane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−96−2 : 2−Ethyl−1,3−hexanediol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

94−96−2 : 2−Ethyl−1,3−hexanediol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

950−37−8 : Methidathion 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

950−37−8 : Methidathion 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−13−6 : Indene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−13−6 : Indene 

 Agonist: 0.0089 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−14−7 : 1,2,3−Benzotriazole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−14−7 : 1,2,3−Benzotriazole 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−16−9 : Benzothiazole 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−16−9 : Benzothiazole 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95266−40−3 : Trinexapac−ethyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95266−40−3 : Trinexapac−ethyl 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−38−5 : 1H−Imidazole−1−ethanol, 2−(8−heptadecenyl)−4,5−dihydro− 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−38−5 : 1H−Imidazole−1−ethanol, 2−(8−heptadecenyl)−4,5−dihydro− 

 Agonist: 0.02 Antagonist: 0.03

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−48−7 : o−Cresol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−48−7 : o−Cresol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−49−8 : 2−Chlorotoluene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−49−8 : 2−Chlorotoluene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−50−1 : 1,2−Dichlorobenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−50−1 : 1,2−Dichlorobenzene 

 Agonist: 0.0034 Antagonist: 0.0086

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−53−4 : 2−Methylaniline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−53−4 : 2−Methylaniline 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−54−5 : 1,2−Phenylenediamine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−54−5 : 1,2−Phenylenediamine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−57−8 : 2−Chlorophenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−57−8 : 2−Chlorophenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−63−6 : 1,2,4−Trimethylbenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−63−6 : 1,2,4−Trimethylbenzene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−65−8 : 3,4−Dimethylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−65−8 : 3,4−Dimethylphenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95737−68−1 : Pyriproxyfen 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95737−68−1 : Pyriproxyfen 

 Agonist: 0.022 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−74−9 : 3−Chloro−4−methylaniline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−74−9 : 3−Chloro−4−methylaniline 

 Agonist: 0.0085 Antagonist: 0.021

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

957−51−7 : Diphenamid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

957−51−7 : Diphenamid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−76−1 : 3,4−Dichloroaniline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−76−1 : 3,4−Dichloroaniline 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−80−7 : 2,4−Diaminotoluene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−80−7 : 2,4−Diaminotoluene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−83−0 : 4−Chloro−1,2−diaminobenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−83−0 : 4−Chloro−1,2−diaminobenzene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−87−4 : 2,5−Dimethylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−87−4 : 2,5−Dimethylphenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−93−2 : 1,2,4,5−Tetramethylbenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−93−2 : 1,2,4,5−Tetramethylbenzene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−94−3 : 1,2,4,5−Tetrachlorobenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−94−3 : 1,2,4,5−Tetrachlorobenzene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−95−4 : 2,4,5−Trichlorophenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

95−95−4 : 2,4,5−Trichlorophenol 

 Agonist: 0.017 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

959−98−8 : Endosulfan I 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

959−98−8 : Endosulfan I 

 Agonist: 0.092 Antagonist: 0.00026

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

960−71−4 : Triphenylborane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

960−71−4 : Triphenylborane 

 Agonist: 0.16 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

96−09−3 : Styrene oxide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

96−09−3 : Styrene oxide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

96182−53−5 : Tebupirimfos 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

96182−53−5 : Tebupirimfos 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

96−18−4 : 1,2,3−Trichloropropane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

96−18−4 : 1,2,3−Trichloropropane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

96−23−1 : 1,3−Dichloro−2−propanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

96−23−1 : 1,3−Dichloro−2−propanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

96−24−2 : 3−Chloro−1,2−propanediol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

96−24−2 : 3−Chloro−1,2−propanediol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

962−58−3 : Diazoxon 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

962−58−3 : Diazoxon 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

96−29−7 : 2−Butanone oxime 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

96−29−7 : 2−Butanone oxime 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

96−41−3 : Cyclopentanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

96−41−3 : Cyclopentanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

96−45−7 : Ethylene thiourea 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

96−45−7 : Ethylene thiourea 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

96−48−0 : 4−Butyrolactone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

96−48−0 : 4−Butyrolactone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

96489−71−3 : Pyridaben 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

96489−71−3 : Pyridaben 

 Agonist: 0.052 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

96−70−8 : 2−tert−Butyl−4−ethylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

96−70−8 : 2−tert−Butyl−4−ethylphenol 

 Agonist: 0.024 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

96−76−4 : 2,4−Di−tert−butylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

96−76−4 : 2,4−Di−tert−butylphenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

96−83−3 : Iopanoic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

96−83−3 : Iopanoic acid 

 Agonist: 0.052 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

97−00−7 : 1−Chloro−2,4−dinitrobenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

97−00−7 : 1−Chloro−2,4−dinitrobenzene 

 Agonist: 0 Antagonist: 0.047

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

97−23−4 : Dichlorophen 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

97−23−4 : Dichlorophen 

 Agonist: 0.017 Antagonist: 0.096

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

97322−87−7 : Troglitazone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

97322−87−7 : Troglitazone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

97−52−9 : 2−Methoxy−4−nitroaniline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

97−52−9 : 2−Methoxy−4−nitroaniline 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

97−53−0 : Eugenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

97−53−0 : Eugenol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

97−54−1 : Isoeugenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

97−54−1 : Isoeugenol 

 Agonist: 0.017 Antagonist: 0.0013

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

97−56−3 : 2−Amino−5−azotoluene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

97−56−3 : 2−Amino−5−azotoluene 

 Agonist: 0.21 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

97−59−6 : Allantoin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

97−59−6 : Allantoin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

97−77−8 : Disulfiram 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

97−77−8 : Disulfiram 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

97−78−9 : N−Dodecanoyl−N−methylglycine 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

97−78−9 : N−Dodecanoyl−N−methylglycine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

97886−45−8 : Dithiopyr 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

97886−45−8 : Dithiopyr 

 Agonist: 0.046 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

97−99−4 : Tetrahydrofurfuryl alcohol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

97−99−4 : Tetrahydrofurfuryl alcohol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98−00−0 : Furfuryl alcohol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98−00−0 : Furfuryl alcohol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98−01−1 : Furfural 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98−01−1 : Furfural 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98−06−6 : tert−Butylbenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98−06−6 : tert−Butylbenzene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98−07−7 : Benzotrichloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98−07−7 : Benzotrichloride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98319−26−7 : Finasteride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98319−26−7 : Finasteride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98−51−1 : 4−tert−Butyltoluene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98−51−1 : 4−tert−Butyltoluene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98−52−2 : 4−tert−Butylcyclohexanol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98−52−2 : 4−tert−Butylcyclohexanol 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98−53−3 : 4−tert−Butylcyclohexanone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98−53−3 : 4−tert−Butylcyclohexanone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98−54−4 : 4−tert−Butylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98−54−4 : 4−tert−Butylphenol 

 Agonist: 0.22 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98−56−6 : 1−Chloro−4−(trifluoromethyl)benzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98−56−6 : 1−Chloro−4−(trifluoromethyl)benzene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98730−04−2 : Benoxacor 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98730−04−2 : Benoxacor 

 Agonist: 0 Antagonist: 1e−04

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98−86−2 : Acetophenone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98−86−2 : Acetophenone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98−87−3 : Benzal chloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98−87−3 : Benzal chloride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98886−44−3 : Fosthiazate 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98886−44−3 : Fosthiazate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98−92−0 : Niacinamide 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98−92−0 : Niacinamide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

989−38−8 : Rhodamine 6G 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

989−38−8 : Rhodamine 6G 

 Agonist: 0 Antagonist: 0.15

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98−95−3 : Nitrobenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98−95−3 : Nitrobenzene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98967−40−9 : Flumetsulam 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

98967−40−9 : Flumetsulam 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−07−0 : 3−Dimethylaminophenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−07−0 : 3−Dimethylaminophenol 

 Agonist: 0.0058 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−08−1 : 3−Nitrotoluene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−08−1 : 3−Nitrotoluene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−30−9 : Dicloran 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−30−9 : Dicloran 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−51−4 : 1,2−Dimethyl−4−nitrobenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−51−4 : 1,2−Dimethyl−4−nitrobenzene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−54−7 : 3,4−Dichloronitrobenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−54−7 : 3,4−Dichloronitrobenzene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−55−8 : 2−Methyl−5−nitroaniline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−55−8 : 2−Methyl−5−nitroaniline 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−59−2 : 2−Methoxy−5−nitroaniline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−59−2 : 2−Methoxy−5−nitroaniline 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99607−70−2 : Cloquintocet−mexyl 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99607−70−2 : Cloquintocet−mexyl 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−62−7 : 1,3−Diisopropylbenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−62−7 : 1,3−Diisopropylbenzene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−63−8 : 1,3−Benzenedicarbonyl dichloride 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−63−8 : 1,3−Benzenedicarbonyl dichloride 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−65−0 : 1,3−Dinitrobenzene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−65−0 : 1,3−Dinitrobenzene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−66−1 : Valproic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−66−1 : Valproic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−71−8 : 4−(Butan−2−yl)phenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−71−8 : 4−(Butan−2−yl)phenol 

 Agonist: 0.21 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−76−3 : Methylparaben 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−76−3 : Methylparaben 

 Agonist: 0.016 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−85−4 : gamma−Terpinene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−85−4 : gamma−Terpinene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−86−5 : alpha−Terpinene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−86−5 : alpha−Terpinene 

 Agonist: 0.029 Antagonist: 0.071

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−87−6 : p−Cymene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−87−6 : p−Cymene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−89−8 : 4−Isopropylphenol 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−89−8 : 4−Isopropylphenol 

 Agonist: 0.028 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−93−4 : 4−Hydroxyacetophenone 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−93−4 : 4−Hydroxyacetophenone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−96−7 : 4−Hydroxybenzoic acid 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−96−7 : 4−Hydroxybenzoic acid 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−97−8 : N,N,4−Trimethylaniline 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−97−8 : N,N,4−Trimethylaniline 

 Agonist: 0.0054 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−99−0 : 4−Nitrotoluene 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

99−99−0 : 4−Nitrotoluene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

999−97−3 : Hexamethyldisilazane 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

999−97−3 : Hexamethyldisilazane 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_34742 : Milbemectin (mixture of 70% Milbemcin A4, 30% Milbemycin A3) 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_34742 : Milbemectin (mixture of 70% Milbemcin A4, 30% Milbemycin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47248 : CI−1018 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47248 : CI−1018 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47255 : CP−465394 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47255 : CP−465394 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47265 : CP−471358 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47265 : CP−471358 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47267 : CP−642931 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47267 : CP−642931 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47291 : CI−1044 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47291 : CI−1044 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47292 : PD 0200347 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47292 : PD 0200347 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47299 : CP−422935 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47299 : CP−422935 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47305 : CP−608039 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47305 : CP−608039 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47311 : GSK163929B 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47311 : GSK163929B 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47325 : SB413217A 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47325 : SB413217A 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47328 : MK−274 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47328 : MK−274 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47330 : PharmaGSID_47330 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47330 : PharmaGSID_47330 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47333 : PharmaGSID_47333 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47333 : PharmaGSID_47333 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47334 : MK−968 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47334 : MK−968 

 Agonist: 0 Antagonist: 0.01

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47342 : SR125047 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47342 : SR125047 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47346 : SSR162369 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47346 : SSR162369 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47351 : SSR240612 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47351 : SSR240612 

 Agonist: 0.0047 Antagonist: 0.0059

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47353 : SSR241586 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47353 : SSR241586 

 Agonist: 0 Antagonist: 0.017

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47362 : SSR150106 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47362 : SSR150106 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47364 : SSR103800 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47364 : SSR103800 

 Agonist: 0 Antagonist: 0.015

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47366 : SAR115740 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47366 : SAR115740 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47374 : SSR161421 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47374 : SSR161421 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47377 : AVE6324 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47377 : AVE6324 

 Agonist: 0.012 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47379 : SSR126768 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47379 : SSR126768 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47383 : AVE3247 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47383 : AVE3247 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47385 : SAR377142 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47385 : SAR377142 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47387 : SAR102779 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47387 : SAR102779 

 Agonist: 0 Antagonist: 0.0097

Concentration (uM)

Receptor Score
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47389 : SAR150640 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47389 : SAR150640 

 Agonist: 0 Antagonist: 0.0036

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47708 : Igepal CO−890 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47708 : Igepal CO−890 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47796 : Formalin 

Concentration (uM)

Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

NOCAS_47796 : Formalin 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score